Oral celecoxib is used to treat hereditary angioedema.
By using oral selegiline statal tablets to treat HAE seizures on demand, the problem of poor adherence to existing injection treatments has been solved, achieving rapid and effective treatment of HAE, especially for the relief of severe and extremely severe seizures.
Patent Information
- Application Number
- CN202580027512.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-12-13
- Filing Date
- 2025-02-07
- Publication Date
- 2026-11-10
AI Technical Summary
Existing treatments for hereditary angioedema (HAE) mainly rely on injections, which have problems such as poor patient compliance, treatment delays, and heavy burden, especially during acute attacks, and there is a lack of effective oral on-demand treatments.
Using selenostat as an oral plasma kallikrein inhibitor, administered in orally disintegrating tablet form, provides a rapid and effective treatment option for HAE episodes on demand.
It achieves rapid relief of HAE attacks, reduces treatment delays, and improves patient compliance. It is particularly effective in treating severe and extremely severe attacks, and avoids the inconvenience of injections.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] This invention relates to the treatment of hereditary angioedema (HAE). In particular, this invention provides on-demand treatment of hereditary angioedema (HAE) by orally administering plasma kallikrein inhibitors to patients in need. Background Technology
[0002] Inhibitors of plasma kallikrein have numerous therapeutic applications, particularly in the treatment of hereditary angioedema.
[0003] Plasma kallikrein (PKa) is a trypsin-like serine protease that releases kinins from kininogen (see KD Bhoola et al., "Kallikrein-Kinin Cascade", Encyclopedia of Respiratory Medicine, pp. 483-493; JW Bryant et al., "Humanplasma kallikrein-kinin system: physiological and biochemical parameters", Cardiovascular and haematological agents in medicinal chemistry, 7, pp. 234-250, 2009; KD Bhoola et al., Pharmacological Rev., 1992, 44, 1; and DJ Campbell, "Towards understanding the kallikrein-kinin system: insights from the measurement of kinin peptides", Brazilian Journal). (of Medical and Biological Research 2000, 33, 665-677). Prokaryotic kallikrein is encoded by a single gene and is primarily synthesized in the liver and other tissues. It is secreted by hepatocytes as a zymogen, which circulates in the plasma as a heterodimeric complex bound to high molecular weight kininogen (HK), which is activated to produce active pKa. Factor XIIa (FXIIa) mediates the conversion of prokaryotic kallikrein to pKa, a serine protease that cleaves high molecular weight kininogen (HK) to produce bradykinin (a potent inflammatory hormone). Kinins are potent mediators of inflammation, acting through G protein-coupled receptors, and kinin antagonists (such as bradykinin receptor antagonists) have previously been investigated as potential therapeutic agents for a variety of conditions (F. Marceau and D. Regoli, Nature Rev., Drug Discovery, 2004, 3, 845-852).
[0004] Activation of the kallikrein-kinin system (KKS) is triggered by a variety of physiological factors (e.g., negatively charged surfaces) and pathological factors that induce conformational changes in FXII, leading to its cleavage and activation by specific proteases such as plasminogen activators (Hofman et al., Clin Rev Allergy Immunol 2016). This may not require a negatively charged surface or be cleaved and activated by misfolded proteins (Maas et al., J Clinical Invest 2008). Plasma kallikreinogen is activated to PKa via FXIIa, and FXII is then mutually activated to FXIIa via PKa, thereby providing positive feedback amplification of the KKS.
[0005] The bioactive peptide bradykinin activates the bradykinin 2 receptor (B2R) expressed on a wide variety of blood vessels, neurons, and immune cell types (Kaplan AP, Joseph K. Pathogenic mechanisms of bradykinin-mediated diseases: dysregulation of an innate inflammatory pathway. Adv Immunol. 2014;121:41-89). The interaction between bradykinin and B2R activates pro-inflammatory signaling pathways that mediate, for example, angioedema, pain, inflammation, neutrophil chemotaxis, vascular hyperpermeability, and vasodilation (see Kaplan et al., Adv Immunol. 2014;121:41-89; and Hopp et al., J Neuroinflammation. 2017 Feb 20;14(1):39).
[0006] PKa is believed to play a role in many inflammatory conditions. The main inhibitor of PKa is serine protease inhibitor C1 esterase inhibitor (C1INH). Individuals with a genetic defect in C1INH levels or function due to mutations in SERPING1 may develop hereditary angioedema (HAE-C1INH), which can cause intermittent swelling of the face, limbs, throat, gastrointestinal tract, and genitals. Plasma from HAE patients has elevated levels of cleaved HK, indicating bradykinin production (PLoS ONE 8(8): e74043. 2013). The use of PKa inhibitors (such as the approved drugs ecallantide, lanadelumab, and berotopralstat) has been shown to be effective in treating HAE-C1INH.
[0007] Hereditary angioedema (HAE) is a rare, inherited disorder characterized by recurrent acute attacks in which fluid accumulates outside blood vessels, obstructing the normal flow of blood or lymph and causing rapid swelling of tissues such as the hands, feet, limbs, face, intestines, or airways. Therefore, “hereditary angioedema” can be defined as any disease characterized by recurrent attacks of bradykinin-mediated angioedema (such as severe swelling) caused by a hereditary dysfunction / defect / mutation. Currently, there are three known classes of HAE: (i) type 1 HAE, (ii) type 2 HAE, and (iii) HAE with normal C1-INH levels and function (HAE-nC1INH). However, the field of HAE is rapidly evolving, so it is anticipated that additional types of HAE may be defined in the future.
[0008] Not wanting to be bound by theory, some believe that type 1 HAE is caused by a mutation in the SERPING1 gene that leads to decreased C1INH levels in the blood. Others, not wanting to be bound by theory, believe that type 2 HAE is caused by a mutation in the SERPING1 gene that leads to dysfunction of C1INH in the blood.
[0009] Unlike HAE types 1 and 2 (also known as HAE-C1INH), the pathophysiology of HAE-nC1INH is heterogeneous and not fully understood. Without being bound by theory, the etiology of HAE-nC1INH is not fully clear, and the underlying genetic dysfunction / defect / mutation may sometimes remain unclear. It is known that the etiology of HAE-nC1INH is not related to decreased C1INH levels or dysfunction (in contrast to HAE types 1 and 2).
[0010] Currently, there are difficulties in diagnosing patients with HAE-nC1INH. In fact, the lack of universally accepted criteria for diagnosing HAE-nC1INH limits the estimation of its prevalence. Currently, HAE-nC1INH can be diagnosed by reviewing family history and noting that angioedema is inherited from a previous generation (and therefore it is hereditary angioedema). HAE-nC1INH can also be diagnosed by identifying the presence of dysfunction / deficiency / mutation in genes (in addition to those associated with C1INH). For example, dysfunction / deficiency / mutation in plasminogen has been reported to cause HAE-nC1INH (see, for example, Veronez et al., Front Med (Lausanne). 2019 Feb 21;6:28; or Recke et al., Clin Transl Allergy. 2019 Feb 14;9:9.). It has also been reported that dysfunction / deficiency / mutation of the F12 gene and factor XII can cause HAE-nC1INH (see, for example, Mansi et al., 2014 The Association for the Publication of the Journal of Internal Medicine, 2015, 277; 585–593; or Maat et al. J Thromb Haemost. 2019 Jan;17(1):183-194). However, the genetic cause in most patients with HAE-nC1INH remains unclear, and this subtype is referred to as HAE-UNK or AE-UNK (Bork K et al. Hereditary angioedema with normal C1-INH with versus without specific F12 gene mutations. Allergy. 2015 Aug;70(8):1004-12, Bork K et al. Gene Mutations Linked to Hereditary Angioedema in Solitary Angioedema Patients With Normal C1 Inhibitor. J Allergy Clin Immunol Pract. 2023 Aug;11(8):2441-2449).Approximately 87% of patients diagnosed with HAE-nC1INH have unknown mutations, thus limiting the utility of genetic testing for establishing a diagnosis.
[0011] An acute hypothermic attack (HAE) typically progresses through three key, clinically distinct phases: an initial prodromal phase (typically lasting up to 12 hours), followed by a swelling phase, and then a absorption phase. Most HAE attacks are announced by prodromal symptoms. Two-thirds of prodromal symptoms appear less than 6 hours before the HAE, and no prodromal symptoms appear more than 24 hours before the HAE (Magerl et al., Clinical and Experimental Dermatology 2014, 39, 298-303). For example, the following prodromal symptoms may begin to be observed: mild swelling (particularly affecting the face and neck), a typical type of abdominal pain, and a characteristic skin redness known as "erythema marginatum." The attack is fully formed when maximum swelling and maximum pain expression (e.g., abdominal attacks), discomfort (e.g., peripheral attacks), or life-threatening conditions (e.g., laryngeal attacks) have been reached. Once the attack has reached its peak, the subsequent time to normal is determined by the time required for the swelling to subside and the time needed for the fluid that has seeped into the tissues to be reabsorbed.
[0012] Synthetic and small-molecule plasma kallikrein inhibitors have been previously described, such as Garrett et al. ("Peptide aldehyde…." J. Peptide Res. 52, 62-71 (1998)), T. Griesbacher et al. ("Involvement of tissue kallikrein but not plasma kallikrein in the development of symptoms mediated by endogenous kinins in acute pancreatitis in rats" British Journal of Pharmacology 137, 692-700 (2002)), Evans ("Selective dipeptide inhibitors of kallikrein" WO03 / 076458), Szelke et al. ("Kininogenase inhibitors" WO92 / 04371), DM Evans et al. (Immunolpharmacology, 32, p115-116 (1996)), Szelke et al. ("Kininogen inhibitors" WO95 / 07921), Antonsson et al. ("New peptide derivatives" WO94 / 29335), J. Corte et al. ("Six membered heterocycles useful as serine protease inhibitors" WO2005 / 123680), J. Stürzbecher et al. (Brazilian J. Med. Biol. Res 27, p1929-34 (1994)), Kettner et al. (US 5,187,157), N. Teno et al. (Chem. Pharm. Bull. 41, p1079-1090) (1993)), WBYoung et al. ("Small molecule inhibitors of plasma kallikrein" Bioorg. Med. Chem. Letts. 16, p2034-2036 (2006)), Okada et al. ("Development of potent and selective plasmin and plasma kallikrein inhibitors and studies on the structure-activity relationship" Chem. Pharm. Bull.)48, p1964-72 (2000)), Steinmetzer et al. ("Trypsin-like serine protease inhibitors and their preparation and use" WO08 / 049595), Zhang et al. ("Discovery of highly potent small molecule kallikrein inhibitors" Medicinal Chemistry 2, p545-553 (2006)), Sinha et al. ("Inhibitors of plasma kallikrein" WO08 / 016883), Shigenaga et al. ("Plasma kallikrein Inhibitors" WO2011 / 118672), and Kolte et al. ("Biochemical characterization of a novel high-affinity and specific kallikrein inhibitor") (Biochemical Characterization of a Novel High-Affinity and Specific Kallikrein Inhibitor), British Journal of Pharmacology (2011), 162(7), 1639-1649. Furthermore, Steinmetzer et al. ("Serine protease inhibitors," WO2012 / 004678) described cyclic peptide analogs as inhibitors of human plasmin and plasma kallikrein.
[0013] As explained above, HAE may manifest in patients exhibiting a genetic deficiency or dysfunction in C1 esterase inhibitors. Therefore, some current treatments for HAE involve administering C1 esterase inhibitors to normalize the deficiency or dysfunction in these inhibitors. Such treatments can be prophylactic (i.e., administered in the absence of acute HAE symptoms to prevent / reduce the likelihood of an acute HAE attack) and / or acute (i.e., administered upon noticing acute HAE symptoms to attempt to terminate the attack or reduce its severity).
[0014] Cinryze® and Haegarda® contain C1 esterase inhibitors and are approved for the prevention of acute HAE attacks (i.e., prophylactic treatment). Treatment with Cinryze® requires a powder-to-solution formulation, which is then injected every 3 or 4 days. Similarly, treatment with Haegarda® requires a powder-to-solution formulation, which is then injected twice weekly. These treatments are not always self-administered by patients, and if so, patients need to visit a clinic for treatment. Therefore, both prophylactic treatments can place a significant financial burden on patients. Furthermore, the FDA product information for Haegarda® states that it "should not be used to treat acute HAE attacks," and therefore, if an HAE attack occurs, the patient may require additional therapy.
[0015] Berinert® and Ruconest® contain C1 esterase inhibitors and are approved for the treatment of acute HAE attacks. Both of these treatments also involve preparing an injectable solution for subsequent injection. This process can be burdensome for patients, especially when they are experiencing an acute HAE attack. Self-administration of the dosage is not always possible, and if self-administration is not possible, medication administration may be significantly delayed, thereby increasing the severity of the patient's acute HAE attack.
[0016] Kalbitor® (active substance: icaratide) and Takhzyro® (active substance: lanadelumab) are selective plasma kallikrein inhibitors approved for medical use in the treatment of HAE. Both are formulated as solutions for injection. Icaratide is a large protein plasma kallikrein inhibitor, and there is a risk of allergic reactions. In fact, the EU marketing authorization application for Kalbitor® was recently withdrawn because the benefits of Kalbitor® allegedly did not outweigh its risks. Lanadelumab is a recombinant fully human IgG1κ light chain monoclonal antibody. Reported adverse reactions to treatment with lanadelumab include allergic reactions, injection site pain, injection site erythema, and injection site bruising. The EMA label for Takhzyro® (active substance: lanadelumab) states that it is “not intended for the treatment of acute HAE episodes” and that “in the case of breakthrough HAE episodes, individualized treatment with approved rescue agents should be used.” Furthermore, as injectable medications, both of these treatments involve a heavy burden on patients.
[0017] Berostat (BCX7353) has been approved in some countries for the prophylactic treatment of HAE (not as on-demand treatment), for example, under the brand name Orladeyo®. Hwang et al. (Immunotherapy (2019) 11(17), 1439–1444) noted that higher doses were associated with more gastrointestinal adverse reactions, indicating increased toxicity at higher levels.
[0018] Furthermore, many molecules in the prior art are characterized by highly polar and ionizable guanidine or amidine functional groups. It is well known that such functional groups can limit intestinal permeability and thus oral bioavailability. For example, Tamie J. Chilcote and Sukanto Sinha (“ASP-634: An Oral Drug Candidate for Diabetic Macular Edema”, ARVO 2012 May 6th - May 9th, 2012, Fort Lauderdale, Florida, Presentation 2240) have reported poor oral bioavailability of ASP-440 (a benzomidine). Absorption has also been reported to be improved by generating prodrugs (such as ASP-634). However, it is well known that prodrugs can have several drawbacks, such as poor chemical stability and potential toxicity from inert carriers or unexpected metabolites. In another report, indoleamides were claimed to potentially overcome problems associated with drugs having poor or insufficient ADME-tox and physicochemical properties, although no inhibition of plasma kallikrein was presented or claimed (Griffioen et al., “Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases”, WO2010142801).
[0019] Other known plasma kallikrein inhibitors in this art are typically small molecules, some of which contain highly polar and ionizable functional groups such as guanidines or amidines. Recently, plasma kallikrein inhibitors not characterized by guanidine or amidine functional groups have been reported. For example, Brandl et al. (“N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides as inhibitors of plasma kallikrein” WO2012 / 017020), Evans et al. (“Benzylamine derivatives as inhibitors of plasma kallikrein” WO2013 / 005045), Allan et al. (“Benzylamine derivatives” WO2014 / 108679), Davie et al. (“Heterocyclic derivates” WO2014 / 188211), and Davie et al. (“N-((het)arylmethyl)-heteroaryl-carboxamidescompounds as plasma kallikrein”). kallikrein inhibitors (N-((hetero)arylmethyl)-heteroaryl-formamide compounds as plasma kallikrein inhibitors)" WO2016 / 083820).
[0020] The applicant has developed a novel series of compounds that act as inhibitors of plasma kallikrein, disclosed in WO2016 / 083820 (PCT / GB2015 / 053615). These compounds exhibit good selectivity for plasma kallikrein. One such compound is N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazol-4-carboxamide.
[0021] The name N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide refers to the structure shown below, which is known by its designation "KVD900". The inn for KVD900 is sebetralstat, which will be used to describe this compound throughout this application.
[0022]
[0023] Sebertus.
[0024] Collett et al.'s WO2019 / 106361 discloses certain dosage forms containing cyproterostil. WO2023 / 209381 discloses orally disintegrating tablets containing cyproterostil. WO2020 / 249977 and WO2022 / 084693 explore therapeutic agents containing cyproterostil for the treatment of HAE.
[0025] Sebatestat met all of its Phase 2 efficacy and safety endpoints (see clinical trial NCT04208412). The results of this Phase 2 study are discussed in WO2022 / 172006.
[0026] To date, no oral treatments have been approved for HAE (see, for example, Craig et al., Int Arch Allergy Immunol. 2014;165(2):119-27. doi: 10.1159 / 000368404; Mager et al., Immunol Allergy Clin North Am. 2017 Aug;37(3):571-584). There are no approved oral on-demand treatments for HAE. Instead, most available treatments are injectable. Injectables have several disadvantages compared to oral treatments, primarily concerning patient compliance. For example, injectables are less convenient than oral treatments, requiring preparation and administration in a suitable environment, and can cause pain at the injection site. Reduced patient compliance can lead to delayed treatment, often resulting in worsening of symptoms or even complete avoidance of treatment. In fact, many patients suffering from HAE simply hope that any attacks will subside on their own to avoid injections. Injectable therapy involves delayed administration because patients may need to obtain a formulation or even travel to the hospital for treatment. Therefore, HAE treatment is often weakened by the delayed administration resulting from the heavy burden on patients. In fact, Maurer M et al. (PLoS ONE 2013;8(2): e53773. doi:10.1371 / journal.pone.0053773) explained that over 60% of patients received their HAE injections more than one hour after the onset of their attack.
[0027] Icatibant (marketed as Firazyr®) is the primary on-demand treatment for HAE and is administered via subcutaneous injection. In a real-world study of HAE patients for whom icibant was available (Maurer M et al. PLoS ONE 2013;8(2): e53773. doi:10.1371 / journal.pone.0053773), less than 40% of treated seizures were treated within 1 hour of onset, with 30% not treated until more than 5 hours after onset. Furthermore, 45% of seizures in this study were not treated at all. Therefore, the need to provide patients with improved treatment options for on-demand treatment of HAE seizures remains unmet.
[0028] Early treatment leads to faster and shorter resolution of HAE seizures (Maurer M et al. PLoS ONE 2013;8(2): e53773. doi:10.1371 / journal.pone.0053773), and therefore early intervention when seizures are anticipated or ongoing is crucial for the desired management of the disease. Nevertheless, current on-demand treatment for HAE patients still relies on injectable therapy, and further patient confidence that oral on-demand therapy can replace injectable therapy would be desirable. If patients are to switch from their current therapy to such an alternative, they must have confidence in any alternative (non-injectable) therapy.
[0029] definition
[0030] The terms “HAE episode,” “HAE episode,” and “epidemic” are used interchangeably in this document. The term “hereditary angioedema” (HAE) refers to any bradykinin-mediated angioedema caused by a hereditary gene dysfunction, defect, or mutation. Therefore, the term “HAE” includes at least type 1 HAE, type 2 HAE, and HAE with normal C1INH levels and function (HAE-nC1INH).
[0031] The selenosterol used in this invention may also be a preferred crystal form (crystal form 1), which exhibits at least the following characteristic X-ray powder diffraction peaks (Cu Kα radiation, expressed in degrees 2θ) at approximately the following positions:
[0032] (1) 11.2, 12.5, 13.2, 14.5 and 16.3; or
[0033] (2) 11.2, 12.5, 13.2, 14.5, 16.3, 17.4 and 17.9; or
[0034] (3) 11.2, 12.5, 13.2, 14.5, 16.3, 17.4, 17.9, 21.2 and 22.0.
[0035] In this context, the term "approximately" refers to an uncertainty of ±0.3 (in degrees 2θ), preferably ±0.2 (in degrees 2θ), with respect to a measurement of degree 2θ.
[0036] Crystal form 1 may also have an X-ray powder diffraction pattern containing characteristic peaks (in degrees 2θ) at approximately 4.4, 11.2, 12.5, 13.2, 14.5, 16.3, 17.4, 17.9, 21.2, 22.0 and 22.6.
[0037] Crystal form 1 can also have the same properties as Figure 1 The X-ray powder diffraction patterns shown are essentially the same.
[0038] In any treatment of the invention described herein, the term "secbetstat" is an abbreviation for "secbetstat (or its pharmaceutical salts and / or solvates)". It will be understood that "its pharmaceutical salts and / or solvates" refers to "its pharmaceutical salts", "its pharmaceutical solvates", and "the pharmaceutical solvates of its salts". The preferred form of secbetstat is the free base form, specifically the anhydrous free base form (where the free base can be kept anhydrous).
[0039] The term "medicinal salt" refers to a physiologically or toxicologically tolerable salt, which can be, for example, a pharmaceutical acid addition salt. For instance, because secbestin contains a basic group (e.g., basic nitrogen), the pharmaceutical acid addition salts that can be formed include hydrochloride, hydrobromide, sulfate, phosphate, acetate, citrate, lactate, tartrate, methanesulfonate, succinate, oxalate, phosphate, ethanesulfonate, toluenesulfonate, benzenesulfonate, naphthalenedisulfonate, maleate, adipic acidate, fumarate, hippurate, camphorate, xinafoate, pacetamidobenzoate, dihydroxybenzoate, hydroxynaphthaleneate, succinate, ascorbate, oleate, and hydrogen sulfate. The preferred pharmaceutical salt of the compound is the hydrochloride.
[0040] It can also form acidic hemisalts, such as hemisulfates.
[0041] For a review of suitable salts, see Stahl and Wermuth's "Handbook of Pharmaceutical Salts: Properties, Selection and Use" (Wiley-VCH, Weinheim, Germany, 2002).
[0042] The term "solvent" is used herein to describe molecular complexes comprising selenostat and one or more pharmaceutical solvent molecules (e.g., ethanol or water). When the solvent is water, the term "hydrate" is used, and to avoid any ambiguity, the term "hydrate" is encompassed by the term "solvent".
[0043] "Sebethelstat" can include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, in which hydrogen is replaced by deuterium or tritium, or in which carbon is... 13 C or 14 Compounds that can be substituted with C are all within the scope of this invention.
[0044] In the context of HAE, “on-demand” treatment refers to administering serfibetalitol based on the treatment need for a specific HAE episode. “On-demand” does not require continuous administration of serfibetalitol at regular intervals (e.g., once a week, twice a week, etc.) regardless of the specific circumstances of the HAE episode. This contrasts with some other known HAE treatments that require continuous and regular medication (e.g., treatments using Cinryze® and Haegarda® as described above). Instead, in the treatment of this invention, serfibetalitol is administered when the patient requires a rapid onset of therapeutic effect. These are discussed in more detail below.
[0045] In any treatment of the invention described herein, the patient is preferably human. HAE can affect patients of all ages. Therefore, human patients can be children (0 years to under 18 years of age) or adults (18 years and older). In any treatment described herein, the patient may be susceptible to angioedema. Specifically, the patient may be 12 years of age or older. The patient may also be 2 years of age or older.
[0046] Human patients can be 2 years old or under 18 years old. Human patients can be 2 years old or under 12 years old. Human patients can be 12 years old or under 18 years old. Patients can be at least 70 years old.
[0047] As used herein, “secondary treatment for HAE seizures” or “secondary treatment” means the administration of any dose of an active pharmaceutical ingredient as needed to treat HAE seizures, and that active pharmaceutical ingredient is not celecoxib (or its pharmaceutical salts and / or solvates). Secondary treatment can be existing HAE treatment. For example, “secondary treatment” can be pdC1INH, rhC1INH, icibant, conestat alfa (Ruconest®), or iccaratide. For the avoidance of doubt, “secondary treatment for HAE seizures” does not include prophylactic treatment for HAE.
[0048] As used herein, the terms “second dose,” “third dose,” “fourth dose,” and “additional dose” all refer to the administration of a dose of cebetastat after the initial dose.
[0049] Unless otherwise stated, “seizure resolution” or “seizure resolution” means that the HAE seizure is cleared without the need for an additional dose of selenostat or a second treatment.
[0050] When used in the context of “symptom relief,” the term “consecutive time points” can refer to assessments spaced 30 minutes apart (especially within 0–4 hours after compound administration). “Consecutive time points” can also refer to assessments spaced 1 hour apart (especially within 4–12 hours after compound administration). “Consecutive time points” can also refer to assessments spaced 3 hours apart (especially within 12–24 hours after compound administration).
[0051] As used herein, the term "orally disintegrating tablet" (ODT) refers to a tablet intended to be placed directly in the mouth and which disintegrates rapidly in saliva before being swallowed. ODTs are not swallowable tablets, such as traditional swallowable tablets or capsules. Summary of the Invention
[0052] The efficacy data from the phase 3 study described in Example 4 confirm that treatment with serbetastat reduces the time required to begin symptom relief, reduces the time required to reduce the severity of attacks, and achieves complete remission. These results are statistically significant.
[0053] More specifically, efficacy data from the Phase 3 study described in Example 4 report that sevimetastine treatment can be used across a wide range of seizure sites and severity, including severe and very severe seizures, and including the neck and above seizures (which may be life-threatening seizure types).
[0054] Furthermore, the data described herein report the efficacy of celetatestat (a plasma kallikrein inhibitor) in patients receiving prophylactic HAE treatment (even when the prophylactic treatment is also a plasma kallikrein inhibitor). More specifically, the data described herein indicate that celetatestat (a plasma kallikrein inhibitor) can be used as needed to treat HAE seizures in patients receiving prophylactic HAE treatment (even when the prophylactic treatment is also a plasma kallikrein inhibitor), even if the HAE seizure is severe or very severe and / or if the HAE seizure is in the neck or above (but not the larynx). Neck and above seizures can be facial seizures (i.e., facial attacks) and / or tongue seizures and / or pharyngeal seizures.
[0055] Phase 3 results report that serbetuxartin provides rapid symptom relief in a broad HAE population (reflecting clinical practice) and is safe and well-tolerated, with a safety profile comparable to placebo. These results can provide patients with further confidence to treat a wide range of HAE seizures, including the most severe ones.
[0056] Treatment of severe and more serious HAE attacks
[0057] As noted above, HAE is a rare and potentially life-threatening genetic disorder characterized by unpredictable and often disabling recurrent episodes of swelling in various parts of the body, including the hands, feet, genitals, abdomen, face, and / or throat. Severe episodes can be life-threatening, and therefore any on-demand treatment that is rapid and effective is crucial.
[0058] Furthermore, current on-demand treatment involves a heavy burden on patients, leading them to delay treatment early enough and often hoping that HAE seizures will resolve on their own, thus delaying the use of injectable treatments. This results in delayed (or even no) treatment. This can lead to more severe seizures, longer recovery times, and the need for more extensive medical intervention. Therefore, there is a particular need for effective treatment of severe and extremely severe seizures, which is precisely the problem addressed by this invention.
[0059] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: on-demand oral administration of secfibetalistat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the HAE episode is a severe or more serious HAE episode. Specifically, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: on-demand oral administration of secfibetalistat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the HAE episode is characterized as “severe” or worse according to the PGI-S scale. In one embodiment, the HAE episode is characterized as “severe” according to the PGI-S scale. In another embodiment, the HAE episode is characterized as “very severe” according to the PGI-S scale.
[0060] The PGI-S is a scale known in the art (see, for example, Allergy Asthma Proc. 2018 Jan 1;39(1):74-80. Doi: 10.2500 / aap.2018.39.4095), which can be used to report the severity of HAE episodes and, for example, can be used to report episodes as “none,” “mild,” “moderate,” “severe,” or “extremely severe.”
[0061] Where applicable, any of the treatments described herein can be used to treat HAE episodes characterized as “severe” or higher according to the PGI-S scale. Specific implementation methods are shown below.
[0062] Specific treatment for severe or more serious HAE attacks
[0063] This invention provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: orally administering, on demand, a first dose of about 300 mg of secbetstatin (or its pharmaceutically acceptable saline and / or solvate) to a patient in need, wherein the HAE attack is characterized as “severe” or worse according to the PGI-S scale. In one embodiment, the HAE attack is characterized as “severe” according to the PGI-S scale. In another embodiment, the HAE attack is characterized as “very severe” according to the PGI-S scale. In one embodiment, the first dose is administered on demand within 1 hour of recognizing symptoms of an acute HAE attack. In another embodiment, the first dose is administered on demand within about 50 minutes, about 40 minutes, about 30 minutes, about 20 minutes, about 10 minutes, or about 5 minutes of recognizing symptoms of an acute HAE attack. In one embodiment, a second dose is not administered to the patient, for example, if the first dose provides sufficient therapeutic efficacy, for example, the attack may subside without the administration of a second dose to the patient.
[0064] This invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, comprising: on-demand oral administration of secfithostat (or its pharmaceutically acceptable saline and / or solvate) to a patient in need, wherein the HAE episode is characterized as “severe” or worse according to the PGI-S scale, and wherein a first dose of about 300 mg of secfithostat (or its pharmaceutically acceptable saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of secfithostat (or its pharmaceutically acceptable saline and / or solvate). In one embodiment, the second dose is administered about 2 hours to about 6 hours after the first dose (more specifically, about 2 hours to about 5 hours, about 2 hours to about 4 hours, or 2 hours to about 3 hours). Preferably, the second dose is administered about 3 hours after the first dose.
[0065] The present invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering secfifeltstat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the HAE episode is characterized as “severe” or above according to the PGI-S scale, and wherein a first dose of about 300 mg of secfifeltstat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of secfifeltstat (or its pharmaceutical saline and / or solvate), wherein the second dose is administered about 2 hours to about 6 hours after the first dose, preferably about 3 hours after the first dose.
[0066] In one embodiment, the third dose is not administered to the patient, for example, if the first and second doses provide sufficient therapeutic efficacy, the attack may subside without the administration of a third dose. In an alternative embodiment, the patient is given a third dose of about 300 mg of secbestat (or its pharmaceutically acceptable saline and / or solvate). The third dose may be administered about 2 hours to about 6 hours after the second dose (more specifically, about 2 hours to about 5 hours, about 2 hours to about 4 hours, or 2 hours to about 3 hours). Preferably, the third dose may be administered about 3 hours after the second dose.
[0067] The present invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering secfifestat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the HAE episode is characterized as “severe” or above according to the PGI-S scale, and wherein the patient is given a first dose of about 300 mg of secfifestat (or its pharmaceutical saline and / or solvate), followed by a second dose of about 300 mg of secfifestat (or its pharmaceutical saline and / or solvate), followed by a third dose of about 300 mg of secfifestat (or its pharmaceutical saline and / or solvate).
[0068] The present invention provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, seftiofur (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the HAE attack is characterized as “severe” or worse according to the PGI-S scale, and wherein the patient is given a first dose of about 300 mg of seftiofur (or its pharmaceutical saline and / or solvate), followed by a second dose of about 300 mg of seftiofur (or its pharmaceutical saline and / or solvate), followed by a third dose of about 300 mg of seftiofur (or its pharmaceutical saline and / or solvate), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, and wherein the third dose is administered about 2 to about 6 hours after the second dose, preferably about 3 hours after the second dose.
[0069] In one embodiment, a fourth dose is not administered to the patient, for example, if the first, second, and third doses provide sufficient therapeutic efficacy, such as the attack subsiding without the fourth dose being administered. In an alternative embodiment, a fourth dose of about 300 mg of secbestat (or its pharmaceutically acceptable saline and / or solvate) is administered to the patient. The fourth dose may be administered about 2 hours to about 6 hours after the third dose (more specifically, about 2 hours to about 5 hours, about 2 hours to about 4 hours, or 2 hours to about 3 hours). Preferably, the fourth dose may be administered about 3 hours after the third dose.
[0070] This invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering secfifestat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the HAE episode is characterized as “severe” or worse according to the PGI-S scale, and wherein the patient is given a first dose of about 300 mg of secfifestat (or its pharmaceutical saline and / or solvate), followed by a second dose of about 300 mg of secfifestat (or its pharmaceutical saline and / or solvate), followed by a third dose of about 300 mg of secfifestat (or its pharmaceutical saline and / or solvate), followed by a fourth dose of about 300 mg of secfifestat (or its pharmaceutical saline and / or solvate).
[0071] This invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering, on-demand, oral secifetrestat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the HAE episode is characterized as “severe” or worse according to the PGI-S scale, and wherein the patient is given a first dose of about 300 mg of secifetrestat (or its pharmaceutical saline and / or solvate), followed by a second dose of about 300 mg of secifetrestat (or its pharmaceutical saline and / or solvate), followed by a third dose of about 300 mg of secifetrestat (or its pharmaceutical saline and / or solvate), followed by a fourth dose of about 300 mg of secifetrestat (or its pharmaceutical saline and / or solvate). mg of seletestat (or its pharmaceutical salt and / or solvate), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, wherein the third dose is administered about 2 to about 6 hours after the second dose, preferably about 3 hours after the second dose, and wherein the fourth dose is administered about 2 to about 6 hours after the third dose, preferably about 3 hours after the third dose.
[0072] In one implementation, no further dose is administered to the patient, for example, the attack subsides without any further dose being administered to the patient, particularly without a fifth dose.
[0073] In any of the above embodiments, each dose is preferably administered as a unit dose. In particular, each unit dose is preferably administered as a tablet (e.g., a film-coated tablet or an orally disintegrating tablet).
[0074] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: on-demand oral administration of secbetalstat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the HAE episode is characterized as “severe” or worse according to the PGI-S scale and wherein the patient is also treated with a prophylactic agent for HAE. In one embodiment, the HAE episode is characterized as “severe” according to the PGI-S scale. In another embodiment, the HAE episode is characterized as “very severe” according to the PGI-S scale.
[0075] Prophylactic treatments for HAE can include PKa binders, bradykinin B2 receptor antagonists, factor XIIa (FXIIa) binders, or C1INH substitutes.
[0076] Prophylactic treatment for HAE can be a pKa binder, preferably a plasma kallikrein inhibitor.
[0077] Prophylactic treatment for HAE can be bradykinin B2 receptor antagonists.
[0078] Prophylactic treatment for HAE can be factor XIIa (FXIIa) binders, preferably FXIIa inhibitors.
[0079] Prophylactic treatment for HAE can be a reduced androgen. Specifically, a reduced androgen can be danazol or oxandrolone. Another prophylactic treatment for HAE can be tranexamic acid. Alternatively, prophylactic treatment for HAE can be a non-androgen therapy.
[0080] Prophylactic agents for HAE may be selected from lanadelumab, garadacimab, berotopralstat, STAR 0215, C1INH replacement therapies (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®), donidalorsen, and deucrictibant. In one embodiment, the prophylactic agent is selected from garadacimab, STAR 0215, C1INH replacement therapies (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®), donidalorsen, and deucrictibant.
[0081] Prophylactic treatment for HAE can be a C1 inhibitor. Specifically, prophylactic treatment can be Cinryze®, Haegarda®, or Berinert®.
[0082] Prophylactic treatments may include lanalidomide or berositol.
[0083] Prophylactic treatment may include lanalidomide.
[0084] Berosstat can be used as a preventative treatment.
[0085] This invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: on-demand oral administration of secfistat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the HAE episode is characterized as “severe” or worse according to the PGI-S scale and wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is a factor XIIa (FXIIa) inhibitor. In one embodiment, the HAE episode is characterized as “severe” according to the PGI-S scale. In another embodiment, the HAE episode is characterized as “very severe” according to the PGI-S scale.
[0086] This invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: on-demand oral administration of secfistat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the HAE episode is characterized as “severe” or worse according to the PGI-S scale and wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is a plasma kallikrein inhibitor. In one embodiment, the HAE episode is characterized as “severe” according to the PGI-S scale. In another embodiment, the HAE episode is characterized as “very severe” according to the PGI-S scale.
[0087] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: on-demand oral administration of secfistat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the HAE episode is characterized as “severe” or worse according to the PGI-S scale and wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is selected from lanaleximab, gardacrumb, berositol, STAR 0215, C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®), donidalosin, and deucrictibant. In one embodiment, the prophylactic agent is selected from gardacrumb, STAR 0215, C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®), donidalosin, and deucrictibant. In one embodiment, the HAE episode is characterized as “severe” according to the PGI-S scale. In another implementation, HAE episodes are characterized as “extremely severe” according to the PGI-S scale.
[0088] This invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: on-demand oral administration of secfistat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the HAE episode is characterized as “severe” or worse according to the PGI-S scale and wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is selected from lanaleximab, berositol, and C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®). In one embodiment, the HAE episode is characterized as “severe” according to the PGI-S scale. In another embodiment, the HAE episode is characterized as “very severe” according to the PGI-S scale.
[0089] This invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: on-demand oral administration of secfistat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the HAE episode is characterized as “severe” or worse according to the PGI-S scale and wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is selected from lanaleximab and berositol. In one embodiment, the HAE episode is characterized as “severe” according to the PGI-S scale. In another embodiment, the HAE episode is characterized as “very severe” according to the PGI-S scale.
[0090] This invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: on-demand oral administration of secfistat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the HAE episode is characterized as “severe” or worse according to the PGI-S scale and wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is lanalalimumab. In one embodiment, the HAE episode is characterized as “severe” according to the PGI-S scale. In another embodiment, the HAE episode is characterized as “very severe” according to the PGI-S scale.
[0091] This invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: on-demand oral administration of secfistat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the HAE episode is characterized as “severe” or worse according to the PGI-S scale and wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is berosstat. In one embodiment, the HAE episode is characterized as “severe” according to the PGI-S scale. In another embodiment, the HAE episode is characterized as “very severe” according to the PGI-S scale.
[0092] This invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: on-demand oral administration of secbetalstat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the HAE episode is characterized as “severe” or worse according to the PGI-S scale and wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is a C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®). In one embodiment, the HAE episode is characterized as “severe” according to the PGI-S scale. In another embodiment, the HAE episode is characterized as “very severe” according to the PGI-S scale.
[0093] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: on-demand oral administration of secbetalstat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the HAE episode is characterized as “severe” or worse according to the PGI-S scale, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the episode subsides without administration of a second dose to the patient. In one embodiment, the HAE episode is characterized as “severe” according to the PGI-S scale. In another embodiment, the HAE episode is characterized as “very severe” according to the PGI-S scale.
[0094] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: on-demand oral administration of secbetalstat (or its pharmaceutically acceptable saline and / or solvate) to a patient in need, wherein the HAE episode is characterized as “severe” or worse according to the PGI-S scale, wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is selected from lanaleximab, dadaximab, berositol, STAR 0215, C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®), donidalosin, and deucrictibant, and wherein the episode subsides without administration of a second dose to the patient. In one embodiment, the prophylactic agent is selected from dadaximab, STAR 0215, C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®), donidalosin, and deucrictibant. In one implementation, a HAE episode is characterized as “severe” according to the PGI-S scale. In another implementation, a HAE episode is characterized as “extremely severe” according to the PGI-S scale.
[0095] This invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, comprising: on-demand oral administration of secfistat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the HAE episode is characterized as “severe” or worse according to the PGI-S scale, wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is selected from lanaleximab, berositol, and C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®), and wherein the episode subsides without administration of a second dose to the patient. In one embodiment, the HAE episode is characterized as “severe” according to the PGI-S scale. In another embodiment, the HAE episode is characterized as “very severe” according to the PGI-S scale.
[0096] This invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: on-demand oral administration of secfistat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the HAE episode is characterized as “severe” or worse according to the PGI-S scale, wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is selected from lanaleximab and berosstat, and wherein the episode resolves without administration of a second dose to the patient. In one embodiment, the HAE episode is characterized as “severe” according to the PGI-S scale. In another embodiment, the HAE episode is characterized as “very severe” according to the PGI-S scale.
[0097] This invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: on-demand oral administration of secfistat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the HAE episode is characterized as “severe” or worse according to the PGI-S scale, wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is lanalalimumab, and wherein the episode resolves without administration of a second dose to the patient. In one embodiment, the HAE episode is characterized as “severe” according to the PGI-S scale. In another embodiment, the HAE episode is characterized as “very severe” according to the PGI-S scale.
[0098] This invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: on-demand oral administration of secfistat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the HAE episode is characterized as “severe” or worse according to the PGI-S scale, wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is berosstat, and wherein the episode subsides without administration of a second dose to the patient. In one embodiment, the HAE episode is characterized as “severe” according to the PGI-S scale. In another embodiment, the HAE episode is characterized as “very severe” according to the PGI-S scale.
[0099] This invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, comprising: on-demand oral administration of secbetalstat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the HAE episode is characterized as “severe” or worse according to the PGI-S scale, wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is a C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®), and wherein the episode subsides without administration of a second dose to the patient. In one embodiment, the HAE episode is characterized as “severe” according to the PGI-S scale. In another embodiment, the HAE episode is characterized as “very severe” according to the PGI-S scale.
[0100] Alternatively, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: on-demand oral administration of secbetalstat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the HAE episode is characterized as “severe” or worse according to the PGI-S scale and wherein the patient is not being treated with prophylactic agents for HAE. In one embodiment, the HAE episode is characterized as “severe” according to the PGI-S scale. In another embodiment, the HAE episode is characterized as “very severe” according to the PGI-S scale.
[0101] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: orally administering, as needed, a first dose of approximately 300 mg of secfistat (or its pharmaceutically acceptable saline and / or solvate) to a patient in need, wherein the HAE episode is characterized as “severe” or worse according to the PGI-S scale and wherein the patient is also treated with a prophylactic agent for HAE. In one embodiment, the HAE episode is characterized as “severe” according to the PGI-S scale. In another embodiment, the HAE episode is characterized as “very severe” according to the PGI-S scale.
[0102] This invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: orally administering, as needed, a first dose of approximately 300 mg of secfistat (or its pharmaceutically acceptable saline and / or solvate) to a patient in need, wherein the HAE episode is characterized as “severe” or worse according to the PGI-S scale and wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is a factor XIIa (FXIIa) inhibitor. In one embodiment, the HAE episode is characterized as “severe” according to the PGI-S scale. In another embodiment, the HAE episode is characterized as “very severe” according to the PGI-S scale.
[0103] This invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: orally administering, as needed, a first dose of approximately 300 mg of secfistat (or its pharmaceutically acceptable saline and / or solvate) to a patient in need, wherein the HAE episode is characterized as “severe” or worse according to the PGI-S scale and wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is a plasma kallikrein inhibitor. In one embodiment, the HAE episode is characterized as “severe” according to the PGI-S scale. In another embodiment, the HAE episode is characterized as “very severe” according to the PGI-S scale.
[0104] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: orally administering, as needed, a first dose of approximately 300 mg of secfistat (or its pharmaceutically acceptable saline and / or solvate) to a patient in need, wherein the HAE episode is characterized as “severe” or worse according to the PGI-S scale and wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is selected from lanaleximab, gardacrumb, berositol, STAR0215, C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®), donidalosin, and deucrictibant. In one embodiment, the prophylactic agent is selected from gardacrumb, STAR0215, C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®), donidalosin, and deucrictibant. In one implementation, a HAE episode is characterized as “severe” according to the PGI-S scale. In another implementation, a HAE episode is characterized as “extremely severe” according to the PGI-S scale.
[0105] This invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: orally administering, as needed, a first dose of approximately 300 mg of secfistat (or its pharmaceutically acceptable saline and / or solvate) to a patient in need, wherein the HAE episode is characterized as “severe” or worse according to the PGI-S scale and wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is selected from lanaleximab, berositol, and C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®). In one embodiment, the HAE episode is characterized as “severe” according to the PGI-S scale. In another embodiment, the HAE episode is characterized as “very severe” according to the PGI-S scale.
[0106] This invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: orally administering, as needed, a first dose of approximately 300 mg of secfistat (or its pharmaceutically acceptable saline and / or solvate) to a patient in need, wherein the HAE episode is characterized as “severe” or worse according to the PGI-S scale and wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is selected from lanaleximab and berosstat. In one embodiment, the HAE episode is characterized as “severe” according to the PGI-S scale. In another embodiment, the HAE episode is characterized as “very severe” according to the PGI-S scale.
[0107] This invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: orally administering, as needed, a first dose of approximately 300 mg of secfistat (or its pharmaceutically acceptable saline and / or solvate) to a patient in need, wherein the HAE episode is characterized as “severe” or worse according to the PGI-S scale and wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is lanalalimumab. In one embodiment, the HAE episode is characterized as “severe” according to the PGI-S scale. In another embodiment, the HAE episode is characterized as “very severe” according to the PGI-S scale.
[0108] This invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: orally administering, as needed, a first dose of approximately 300 mg of secfistat (or its pharmaceutically acceptable saline and / or solvate) to a patient in need, wherein the HAE episode is characterized as “severe” or worse according to the PGI-S scale and wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is berosstat. In one embodiment, the HAE episode is characterized as “severe” according to the PGI-S scale. In another embodiment, the HAE episode is characterized as “very severe” according to the PGI-S scale.
[0109] This invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: orally administering, as needed, a first dose of approximately 300 mg of secbetstatin (or its pharmaceutically acceptable saline and / or solvate) to a patient in need, wherein the HAE episode is characterized as “severe” or worse according to the PGI-S scale and wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is a C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®). In one embodiment, the HAE episode is characterized as “severe” according to the PGI-S scale. In another embodiment, the HAE episode is characterized as “very severe” according to the PGI-S scale.
[0110] Alternatively, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: orally administering, as needed, a first dose of about 300 mg of secfistat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the HAE episode is characterized as “severe” or worse according to the PGI-S scale and wherein the patient is not being treated with any prophylactic HAE medication. In one embodiment, the HAE episode is characterized as “severe” according to the PGI-S scale. In another embodiment, the HAE episode is characterized as “very severe” according to the PGI-S scale.
[0111] In any of the above embodiments, the HAE seizure is selected from laryngeal seizures, neck and above seizures, abdominal seizures, subcutaneous seizures, arm seizures, hand seizures, leg seizures, foot seizures, head seizures, facial seizures, neck seizures, trunk seizures, and genital seizures. In one embodiment, the HAE seizure is a laryngeal seizure. In one embodiment, the HAE seizure is a neck and above seizure. In one embodiment, the HAE seizure is a neck and above seizure but not a laryngeal seizure. In one embodiment, the HAE seizure is an abdominal seizure. In one embodiment, the HAE seizure is a subcutaneous seizure. In one embodiment, the HAE seizure is an arm seizure. In one embodiment, the HAE seizure is a hand seizure. In one embodiment, the HAE seizure is a leg seizure. In one embodiment, the HAE seizure is a foot seizure. In one embodiment, the HAE seizure is a head seizure. In one embodiment, the HAE seizure is a facial seizure. In one embodiment, the HAE seizure is a neck seizure. In one embodiment, the HAE seizure is a trunk seizure. In one embodiment, the HAE seizure is a genital seizure.
[0112] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: on-demand oral administration of secbetalstat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the HAE episode is characterized as “severe” or worse according to the PGI-S scale and wherein the HAE episode is a laryngeal episode. In one embodiment, the HAE episode is characterized as “severe” according to the PGI-S scale. In another embodiment, the HAE episode is characterized as “very severe” according to the PGI-S scale.
[0113] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: on-demand oral administration of secbetalstat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the HAE episode is characterized as “mild” or worse according to the PGI-S scale and wherein the HAE episode is a laryngeal episode. In one embodiment, the HAE episode is characterized as “mild” according to the PGI-S scale.
[0114] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: on-demand oral administration of secbetalstat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the HAE episode is characterized as “moderate” or above according to the PGI-S scale and wherein the HAE episode is a laryngeal episode. In one embodiment, the HAE episode is characterized as “moderate” according to the PGI-S scale.
[0115] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering sevirate statol (or its pharmaceutical saline and / or solvate) orally to a patient in need as needed, wherein the HAE episode is a laryngeal episode, and wherein the episode subsides without administration of a second dose to the patient.
[0116] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: on-demand oral administration of secbetalstat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the HAE episode is characterized as “severe” or worse according to the PGI-S scale, wherein the HAE episode is a laryngeal episode, and wherein the episode subsides without administration of a second dose to the patient. In one embodiment, the HAE episode is characterized as “severe” according to the PGI-S scale. In another embodiment, the HAE episode is characterized as “very severe” according to the PGI-S scale.
[0117] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: on-demand oral administration of secbetalstat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the HAE episode is characterized as “mild” or worse according to the PGI-S scale, wherein the HAE episode is a laryngeal episode, and wherein the episode subsides without administration of a second dose to the patient. In one embodiment, the HAE episode is characterized as “mild” according to the PGI-S scale.
[0118] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: on-demand oral administration of secbetalstat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the HAE episode is characterized as “moderate” or higher according to the PGI-S scale, wherein the HAE episode is a laryngeal episode, and wherein the episode subsides without administration of a second dose to the patient. In one embodiment, the HAE episode is characterized as “moderate” according to the PGI-S scale.
[0119] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering sevirate statol (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the HAE episode is characterized as “severe” or above according to the PGI-S scale and wherein the HAE episode occurs in the neck or above.
[0120] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: on-demand oral administration of sevirate statol (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the HAE episode is characterized as “severe” or above according to the PGI-S scale and wherein the HAE episode is an abdominal episode.
[0121] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering sevirate statol (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the HAE episode is characterized as “severe” or above according to the PGI-S scale and wherein the HAE episode is a subcutaneous episode.
[0122] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: on-demand oral administration of sevirate statol (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the HAE episode is characterized as “severe” or above according to the PGI-S scale and wherein the HAE episode is an episode in the neck or above but not in the larynx.
[0123] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering, on demand, a first dose of approximately 300 mg of celefatestat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the HAE episode is characterized as “severe” or above according to the PGI-S scale and wherein the HAE episode is a laryngeal episode.
[0124] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering, on demand, a first dose of approximately 300 mg of celefatestat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the HAE episode is characterized as “severe” or above according to the PGI-S scale, wherein the HAE episode is a laryngeal episode, and wherein the episode subsides without administration of a second dose to the patient.
[0125] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering, on demand, a first dose of approximately 300 mg of celefatestat (or its pharmaceutical salt and / or solvate) orally to a patient in need, wherein the HAE episode is characterized as “mild” or above according to the PGI-S scale, wherein the HAE episode is a laryngeal episode, and wherein the episode subsides without administration of a second dose to the patient.
[0126] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering, on demand, a first dose of approximately 300 mg of secbetalstat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the HAE episode is characterized as “moderate” or above according to the PGI-S scale, wherein the HAE episode is a laryngeal episode, and wherein the episode subsides without administration of a second dose to the patient.
[0127] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering, on demand, a first dose of approximately 300 mg of celefatestat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the HAE episode is characterized as “severe” or above according to the PGI-S scale and wherein the HAE episode occurs in the neck or above.
[0128] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering, on demand, a first dose of approximately 300 mg of celefatestat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the HAE episode is characterized as “severe” or above according to the PGI-S scale and wherein the HAE episode is an abdominal episode.
[0129] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering, on demand, a first dose of approximately 300 mg of celefatestat (or its pharmaceutical salt and / or solvate) orally to a patient in need, wherein the HAE episode is characterized as “severe” or above according to the PGI-S scale and wherein the HAE episode is a subcutaneous episode.
[0130] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering, on demand, a first dose of approximately 300 mg of celefatestat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the HAE episode is characterized as “severe” or above according to the PGI-S scale and wherein the HAE episode is an episode in the neck or above but not in the larynx.
[0131] For the avoidance of doubt, any of the embodiments described above regarding the treatment of severe or more serious HAE episodes according to the present invention may, where appropriate, be combined with any of the embodiments described below regarding the treatment of HAE episodes in patients receiving prophylactic treatment, medication, treatment of HAE episodes in the neck and above, specific combination therapies, and drug-drug interactions. It is intended that any of these embodiments may be combined.
[0132] Treatment of HAE attacks in patients receiving prophylactic treatment
[0133] As noted above, existing treatments for HAE are either administered on demand or preventative. On-demand treatment is administered in response to a specific seizure to reduce its severity (e.g., at the initial signs of seizure symptoms). Preventative treatment involves the continuous and regular taking of medication to reduce the likelihood of a seizure occurring, i.e., it is not a response to a single seizure.
[0134] The overall goal of long-term preventative treatment is to achieve a seizure-free state. However, existing preventative treatments are often not entirely effective, with patients receiving preventative treatment still experiencing HAE seizures. This is illustrated in Example 4 and... Figure 2 and 3 Data on the incidence of seizures reported from patients receiving prophylactic treatment confirm this. Therefore, it is generally recommended that HAE patients carry on-demand medication even while receiving prophylactic treatment (such treatment is sometimes referred to as "rescue therapy"). In fact, both Takhzyro® and Orladeyo® have approved labels recommending that patients carry rescue medication in case of HAE seizures. Therefore, patients receiving prophylactic treatment still face the risk of seizures and continue to bear a burden in their daily lives, largely due to the challenges associated with current parenteral on-demand therapy, as described above.
[0135] In particular, the location, duration, and severity of attacks were similar between patients receiving preventative treatment and those receiving only on-demand treatment (see [link to relevant documentation]). Figure 2 and 3The distribution of seizure severity (PGI-S) at baseline was shown in a phase 3 clinical trial examining secretostigmine (the results of which are reported in this paper). Notably, even with prophylactic treatment, patients receiving prophylactic treatment still experienced severe and very severe seizures (see also Maurer M, Magerl M, Betschel S, et al., The international WAO / EAACI guideline for the management of hereditary angioedema - The 2021 revision and update. Allergy. 2022; 77: 1961-1990. doi:10.1111 / all.15214). Therefore, regardless of their current treatment regimen (or not receiving treatment), all patients with HAE will benefit from effective on-demand treatment of HAE, which is precisely a need addressed by this invention.
[0136] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on demand, a first dose of about 300 mg of secbetstatin (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic treatment agent for HAE.
[0137] The present invention provides seviratestor (or its pharmaceutical salts and / or solvates) for on-demand treatment of hereditary angioedema (HAE) attacks, comprising: administering, on-demand, a first dose of about 300 mg of seviratestor (or its pharmaceutical salts and / or solvates) orally to a patient in need, wherein the patient is also being treated with a prophylactic agent for HAE.
[0138] This invention provides a preventive therapeutic agent for HAE, used to treat hereditary angioedema (HAE), wherein a first dose of 300 mg of secbetalstat (or its pharmaceutical saline and / or solvate) is administered orally to the patient as needed to treat HAE attacks.
[0139] This invention provides seviratestostat (or its pharmaceutical salts and / or solvates) and a prophylactic treatment for HAE, for treating hereditary angioedema (HAE) in patients in need, comprising: administering the prophylactic treatment for HAE to the patient and orally administering a first dose of about 300 mg of seviratestostat (or its pharmaceutical salts and / or solvates) to treat HAE attacks as needed.
[0140] For the avoidance of doubt, any of the above-described embodiments regarding the treatment of severe or more serious HAE attacks according to the present invention, or the following descriptions regarding medication, treatment of HAE attacks in the neck and above, specific combination therapies, and drug-drug interactions, may be considered for combination with any of the embodiments described herein regarding the treatment of HAE attacks in patients receiving prophylactic treatment, where appropriate. It is intended that any of these embodiments may be combined.
[0141] Therefore, any of the treatments described herein can be used to treat HAE episodes where the patient is also being treated with prophylactic agents for HAE. Specific implementation methods are shown below.
[0142] Specific treatment for HAE attacks in patients receiving preventative treatment
[0143] In any of the implementation schemes described herein, secbetalistat and the prophylactic agent for HAE can be administered simultaneously, alone, or sequentially. For the avoidance of doubt, secbetalistat and the prophylactic agent for HAE are not required to be given at the same time; that is, secbetalistat and the prophylactic agent for HAE can be given at different times of the day. In fact, this is to be expected, as patients typically take their prophylactic agent at a specific time, while on-demand treatment will be used as needed after an HAE episode is identified.
[0144] In any of the embodiments described herein, the first dose may be administered as needed within one hour of recognizing symptoms of an acute HAE attack. In another embodiment, the first dose may be administered as needed within approximately 50 minutes, approximately 40 minutes, approximately 30 minutes, approximately 20 minutes, approximately 10 minutes, approximately 6 minutes, or approximately 5 minutes of recognizing symptoms of an acute HAE attack. In one embodiment, a second dose is not administered to the patient, for example, if the first dose provides sufficient therapeutic efficacy, such as if the attack can subside without the administration of a second dose.
[0145] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: on-demand oral administration of secfithostat (or its pharmaceutically acceptable saline and / or solvate) to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein a first dose of about 300 mg of secfithostat (or its pharmaceutically acceptable saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of secfithostat (or its pharmaceutically acceptable saline and / or solvate). In one embodiment, the second dose is administered about 2 hours to about 6 hours after the first dose (more specifically, about 2 hours to about 5 hours, about 2 hours to about 4 hours, 2 hours to about 3 hours). Preferably, the second dose is administered about 3 hours after the first dose.
[0146] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, secbetalstat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein a first dose of about 300 mg of secbetalstat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of secbetalstat (or its pharmaceutical saline and / or solvate), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose.
[0147] In one embodiment, the third dose is not administered to the patient, for example, if the first and second doses provide sufficient therapeutic efficacy, such as the attack subsiding without the third dose being administered. In an alternative embodiment, the patient is given a third dose of about 300 mg of secbestat (or its pharmaceutically acceptable saline and / or solvate). The third dose may be administered about 2 hours to about 6 hours after the second dose (more specifically, about 2 hours to about 5 hours, about 2 hours to about 4 hours, or 2 hours to about 3 hours). Preferably, the third dose may be administered about 3 hours after the second dose.
[0148] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering secfifeltstat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the patient is given a first dose of about 300 mg of secfifeltstat (or its pharmaceutical saline and / or solvate), followed by a second dose of about 300 mg of secfifeltstat (or its pharmaceutical saline and / or solvate), followed by a third dose of about 300 mg of secfifeltstat (or its pharmaceutical saline and / or solvate).
[0149] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, seftiofur (or its pharmaceutical saponins and / or solvates) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the patient is given a first dose of about 300 mg of seftiofur (or its pharmaceutical saponins and / or solvates), followed by a second dose of about 300 mg of seftiofur (or its pharmaceutical saponins and / or solvates), followed by a third dose of about 300 mg of seftiofur (or its pharmaceutical saponins and / or solvates), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, and wherein the third dose is administered about 2 to about 6 hours after the second dose, preferably about 3 hours after the second dose.
[0150] In one embodiment, the fourth dose is not administered to the patient, for example, if the first, second, and third doses provide sufficient therapeutic efficacy, such as the attack subsiding without the fourth dose being administered. In an alternative embodiment, the patient is given a fourth dose of about 300 mg of secbestat (or its pharmaceutically acceptable saline and / or solvate). The fourth dose may be administered about 2 hours to about 6 hours after the third dose (more specifically, about 2 hours to about 5 hours, about 2 hours to about 4 hours, or 2 hours to about 3 hours). Preferably, the fourth dose may be administered about 3 hours after the third dose.
[0151] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, secifetrestat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the patient is given a first dose of about 300 mg of secifetrestat (or its pharmaceutical saline and / or solvate), followed by a second dose of about 300 mg of secifetrestat (or its pharmaceutical saline and / or solvate), followed by a third dose of about 300 mg of secifetrestat (or its pharmaceutical saline and / or solvate), followed by a fourth dose of about 300 mg of secifetrestat (or its pharmaceutical saline and / or solvate).
[0152] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: on-demand oral administration of secfithostat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the patient is given a first dose of about 300 mg of secfithostat (or its pharmaceutical saline and / or solvate), followed by a second dose of about 300 mg of secfithostat (or its pharmaceutical saline and / or solvate), followed by a third dose of about 300 mg of secfithostat (or its pharmaceutical saline and / or solvate), followed by a fourth dose of about 300 mg of secfithostat (or its pharmaceutical saline and / or solvate). mg of seletestat (or its pharmaceutical salt and / or solvate), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, wherein the third dose is administered about 2 to about 6 hours after the second dose, preferably about 3 hours after the second dose, and wherein the fourth dose is administered about 2 to about 6 hours after the third dose, preferably about 3 hours after the third dose.
[0153] In one implementation, no further dose is administered to the patient, for example, the attack subsides without any further dose being administered to the patient, particularly without a fifth dose.
[0154] In any of the above embodiments, each dose is preferably administered as a unit dose. In particular, each unit dose is preferably administered as a tablet (e.g., a film-coated tablet or an orally disintegrating tablet).
[0155] In any of the above implementation schemes, the prophylactic treatment for HAE may be a PKa binder, a bradykinin B2 receptor antagonist, a factor XIIa (FXIIa) binder, or a C1INH substitute.
[0156] Prophylactic treatment for HAE can be a pKa binder, preferably a plasma kallikrein inhibitor.
[0157] Prophylactic treatment for HAE can be bradykinin B2 receptor antagonists.
[0158] Prophylactic treatment for HAE can be factor XIIa (FXIIa) binders, preferably FXIIa inhibitors.
[0159] Prophylactic treatment for HAE can be a reduced-dose androgen. Specifically, a reduced-dose androgen can be danazol or oxandrolone. Prophylactic treatment for HAE can also be tranexamic acid. Alternatively, prophylactic treatment for HAE can be non-androgen therapy.
[0160] Prophylactic agents for HAE may be selected from lanazalimumab, dadaxisab, berositol, STAR 0215, C1INH replacement therapies (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®), donidalosin, and deucrictibant. In one embodiment, the prophylactic agent is selected from dadaxisab, STAR 0215, C1INH replacement therapies (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®), donidalosin, and deucrictibant.
[0161] Prophylactic treatment for HAE can be a C1 inhibitor. Specifically, prophylactic treatment can be Cinryze®, Haegarda®, or Berinert®.
[0162] Prophylactic treatments may include lanalidomide or berositol.
[0163] Prophylactic treatment may include lanalidomide.
[0164] Berosstat can be used as a preventative treatment.
[0165] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, a first dose of approximately 300 mg of secbetalstat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is a factor XIIa (FXIIa) inhibitor.
[0166] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering secfibetalistat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein a first dose of about 300 mg of secfibetalistat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of secfibetalistat (or its pharmaceutical saline and / or solvate), wherein the prophylactic agent is a factor XIIa (FXIIa) inhibitor.
[0167] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, secifetrestat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein a first dose of about 300 mg of secifetrestat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of secifetrestat (or its pharmaceutical saline and / or solvate), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, and wherein the prophylactic agent is a factor XIIa (FXIIa) inhibitor.
[0168] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering secfifeltstat (or its pharmaceutical saline and / or solvate) orally to a patient in need as needed, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the patient is given a first dose of about 300 mg of secfifeltstat (or its pharmaceutical saline and / or solvate), followed by a second dose of about 300 mg of secfifeltstat (or its pharmaceutical saline and / or solvate), followed by a third dose of about 300 mg of secfifeltstat (or its pharmaceutical saline and / or solvate), and wherein the prophylactic agent is a factor XIIa (FXIIa) inhibitor.
[0169] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, seftiofur (or its pharmaceutical saponins and / or solvates) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the patient is given a first dose of about 300 mg of seftiofur (or its pharmaceutical saponins and / or solvates), followed by a second dose of about 300 mg of seftiofur (or its pharmaceutical saponins and / or solvates), followed by a third dose of about 300 mg of seftiofur (or its pharmaceutical saponins and / or solvates), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, and wherein the third dose is administered about 2 to about 6 hours after the second dose, preferably about 3 hours after the second dose, and wherein the prophylactic agent is a factor XIIa (FXIIa) inhibitor.
[0170] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, secifetrestat (or its pharmaceutically acceptable saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the patient is given a first dose of about 300 mg of secifetrestat (or its pharmaceutically acceptable saline and / or solvate), followed by a second dose of about 300 mg of secifetrestat (or its pharmaceutically acceptable saline and / or solvate), followed by a third dose of about 300 mg of secifetrestat (or its pharmaceutically acceptable saline and / or solvate), followed by a fourth dose of about 300 mg of secifetrestat (or its pharmaceutically acceptable saline and / or solvate), and wherein the prophylactic agent is a factor XIIa (FXIIa) inhibitor.
[0171] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: on-demand oral administration of secfithostat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the patient is given a first dose of about 300 mg of secfithostat (or its pharmaceutical saline and / or solvate), followed by a second dose of about 300 mg of secfithostat (or its pharmaceutical saline and / or solvate), followed by a third dose of about 300 mg of secfithostat (or its pharmaceutical saline and / or solvate), followed by a fourth dose of about 300 mg of secfithostat (or its pharmaceutical saline and / or solvate). mg of selenostat (or its pharmaceutical salt and / or solvate), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, wherein the third dose is administered about 2 to about 6 hours after the second dose, preferably about 3 hours after the second dose, and wherein the fourth dose is administered about 2 to about 6 hours after the third dose, preferably about 3 hours after the third dose, and wherein the prophylactic therapeutic agent is a factor XIIa (FXIIa) inhibitor.
[0172] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on demand, a first dose of approximately 300 mg of secbetstatin (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is a plasma kallikrein inhibitor.
[0173] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering secfifestat (or its pharmaceutical saline and / or solvate) orally to a patient in need as needed, wherein the patient is also treated with a prophylactic agent for HAE, and wherein a first dose of about 300 mg of secfifestat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of secfifestat (or its pharmaceutical saline and / or solvate), wherein the prophylactic agent is a plasma kallikrein inhibitor.
[0174] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, secifetrestat (or its pharmaceutical saponins and / or solvates) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein a first dose of about 300 mg of secifetrestat (or its pharmaceutical saponins and / or solvates) is administered to the patient, followed by a second dose of about 300 mg of secifetrestat (or its pharmaceutical saponins and / or solvates), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, and wherein the prophylactic agent is a plasma kallikrein inhibitor.
[0175] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, secifetrestat (or its pharmaceutically acceptable saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the patient is given a first dose of about 300 mg of secifetrestat (or its pharmaceutically acceptable saline and / or solvate), followed by a second dose of about 300 mg of secifetrestat (or its pharmaceutically acceptable saline and / or solvate), followed by a third dose of about 300 mg of secifetrestat (or its pharmaceutically acceptable saline and / or solvate), and wherein the prophylactic agent is a plasma kallikrein inhibitor.
[0176] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, seftiofur (or its pharmaceutical saponins and / or solvates) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the patient is given a first dose of about 300 mg of seftiofur (or its pharmaceutical saponins and / or solvates), followed by a second dose of about 300 mg of seftiofur (or its pharmaceutical saponins and / or solvates), followed by a third dose of about 300 mg of seftiofur (or its pharmaceutical saponins and / or solvates), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, and wherein the third dose is administered about 2 to about 6 hours after the second dose, preferably about 3 hours after the second dose, and wherein the prophylactic agent is a plasma kallikrein inhibitor.
[0177] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, secifetrestat (or its pharmaceutically acceptable saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the patient is given a first dose of about 300 mg of secifetrestat (or its pharmaceutically acceptable saline and / or solvate), followed by a second dose of about 300 mg of secifetrestat (or its pharmaceutically acceptable saline and / or solvate), followed by a third dose of about 300 mg of secifetrestat (or its pharmaceutically acceptable saline and / or solvate), followed by a fourth dose of about 300 mg of secifetrestat (or its pharmaceutically acceptable saline and / or solvate), and wherein the prophylactic agent is a plasma kallikrein inhibitor.
[0178] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: on-demand oral administration of secfithostat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the patient is given a first dose of about 300 mg of secfithostat (or its pharmaceutical saline and / or solvate), followed by a second dose of about 300 mg of secfithostat (or its pharmaceutical saline and / or solvate), followed by a third dose of about 300 mg of secfithostat (or its pharmaceutical saline and / or solvate), followed by a fourth dose of about 300 mg of secfithostat (or its pharmaceutical saline and / or solvate). mg of celefetrazol (or its pharmaceutical salt and / or solvate), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, wherein the third dose is administered about 2 to about 6 hours after the second dose, preferably about 3 hours after the second dose, and wherein the fourth dose is administered about 2 to about 6 hours after the third dose, preferably about 3 hours after the third dose, and wherein the prophylactic therapeutic agent is a plasma kallikrein inhibitor.
[0179] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering, on demand, a first oral dose of approximately 300 mg of secfistat (or its pharmaceutically acceptable saline and / or solvate) to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is selected from lanaleximab, gardacrumb, berositol, STAR 0215, C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®), donidalosin, and deucrictibant. In one embodiment, the prophylactic agent is selected from gardacrumb, STAR 0215, C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®), donidalosin, and deucrictibant.
[0180] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering, on-demand, secbetalstat (or its pharmaceutically acceptable saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein a first dose of about 300 mg of secbetalstat (or its pharmaceutically acceptable saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of secbetalstat (or its pharmaceutically acceptable saline and / or solvate), wherein the prophylactic agent is selected from lanaleximab, caldacron, berostitol, STAR0215, C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®), donidalosin, and deucrictibant. In one implementation, the prophylactic treatment agent is selected from dadaximab, STAR 0215, C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert® or Haegarda®), donidalosin, and deucrictibant.
[0181] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, oral secifettostat (or its pharmaceutically acceptable saline and / or solvate) to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein a first dose of about 300 mg of secifettostat (or its pharmaceutically acceptable saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of secifettostat (or its pharmaceutically acceptable saline and / or solvate), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, and wherein the prophylactic agent is selected from lanaleximab, caldacron, berositol, STAR0215, C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®), donidalosin, and deucrictibant. In one implementation, the prophylactic treatment agent is selected from dadaximab, STAR 0215, C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert® or Haegarda®), donidalosin, and deucrictibant.
[0182] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering, on-demand, orally to a patient in need secbetelstat (or its pharmaceutically acceptable saline and / or solvate), wherein the patient is also treated with a prophylactic agent for HAE, and wherein the patient is given a first dose of about 300 mg of secbetelstat (or its pharmaceutically acceptable saline and / or solvate), followed by a second dose of about 300 mg of secbetelstat (or its pharmaceutically acceptable saline and / or solvate), followed by a third dose of about 300 mg of secbetelstat (or its pharmaceutically acceptable saline and / or solvate), and wherein the prophylactic agent is selected from lanaleximab, caldacron, berositol, STAR 0215, C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®), donidalosin, and deucrictibant. In one implementation, the prophylactic treatment agent is selected from dadaximab, STAR 0215, C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert® or Haegarda®), donidalosin, and deucrictibant.
[0183] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: on-demand oral administration of secfistat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the patient is given a first dose of about 300 mg of secfistat (or its pharmaceutical saline and / or solvate), followed by a second dose of about 300 mg of secfistat (or its pharmaceutical saline and / or solvate), followed by a third dose of about 300 mg of secfistat (or its pharmaceutical saline and / or solvate), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, and wherein the third dose is administered about 2 to about 6 hours after the second dose, preferably about 3 hours after the second dose, and wherein the prophylactic agent is selected from lanaleximab, caldacrumb, berositol, STAR. STAR 0215, C1INH replacement therapies (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®), donidalosin, and deucrictibant. In one implementation, the prophylactic treatment agent is selected from dadaxisab, STAR 0215, C1INH replacement therapies (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®), donidalosin, and deucrictibant.
[0184] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: on-demand oral administration of secfibetalistat (or its pharmaceutically acceptable saline and / or solvate) to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the patient is given a first dose of about 300 mg of secfibetalistat (or its pharmaceutically acceptable saline and / or solvate), followed by a second dose of about 300 mg of secfibetalistat (or its pharmaceutically acceptable saline and / or solvate), followed by a third dose of about 300 mg of secfibetalistat (or its pharmaceutically acceptable saline and / or solvate), followed by a fourth dose of about 300 mg of secfibetalistat (or its pharmaceutically acceptable saline and / or solvate), and wherein the prophylactic agent is selected from lanaleximab, caldacrumb, berositol, STAR. STAR 0215, C1INH replacement therapies (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®), donidalosin, and deucrictibant. In one implementation, the prophylactic treatment agent is selected from dadaxisab, STAR 0215, C1INH replacement therapies (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®), donidalosin, and deucrictibant.
[0185] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: on-demand oral administration of secfithostat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the patient is given a first dose of about 300 mg of secfithostat (or its pharmaceutical saline and / or solvate), followed by a second dose of about 300 mg of secfithostat (or its pharmaceutical saline and / or solvate), followed by a third dose of about 300 mg of secfithostat (or its pharmaceutical saline and / or solvate), followed by a fourth dose of about 300 mg of secfithostat (or its pharmaceutical saline and / or solvate). The dosage of 1 mg of cefixime (or its pharmaceutically acceptable salt and / or solvate) is specified, wherein the second dose is administered approximately 2 to 6 hours after the first dose, preferably approximately 3 hours after the first dose; wherein the third dose is administered approximately 2 to 6 hours after the second dose, preferably approximately 3 hours after the second dose; and wherein the fourth dose is administered approximately 2 to 6 hours after the third dose, preferably approximately 3 hours after the third dose; and wherein the prophylactic agent is selected from lanalalimumab, gardasiramumab, berositol, STAR 0215, C1INH replacement therapies (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®), donidalosin, and deucrictibant. In one embodiment, the prophylactic agent is selected from gardasiramumab, STAR 0215, C1INH replacement therapies (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®), donidalosin, and deucrictibant.
[0186] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering, on-demand, a first dose of approximately 300 mg of secfistat (or its pharmaceutically acceptable saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is selected from lanaleximab, berositol, and C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®).
[0187] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering, on-demand, secfifeltistat (or its pharmaceutically acceptable saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein a first dose of about 300 mg of secfifeltistat (or its pharmaceutically acceptable saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of secfifeltistat (or its pharmaceutically acceptable saline and / or solvate), wherein the prophylactic agent is selected from lanaleximab, berositol, and C1INH replacement therapies (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®).
[0188] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, oral secifetrestat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein a first dose of about 300 mg of secifetrestat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of secifetrestat (or its pharmaceutical saline and / or solvate), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, and wherein the prophylactic agent is selected from lanaleximab, berositol, and C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®).
[0189] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering, on-demand, orally to a patient in need secbetelstat (or its pharmaceutically acceptable saline and / or solvate), wherein the patient is also treated with a prophylactic agent for HAE, and wherein the patient is given a first dose of about 300 mg of secbetelstat (or its pharmaceutically acceptable saline and / or solvate), followed by a second dose of about 300 mg of secbetelstat (or its pharmaceutically acceptable saline and / or solvate), followed by a third dose of about 300 mg of secbetelstat (or its pharmaceutically acceptable saline and / or solvate), and wherein the prophylactic agent is selected from lanaleximab, berositol, and C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®).
[0190] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: on-demand oral administration of secfibetalistat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the patient is given a first dose of about 300 mg of secfibetalistat (or its pharmaceutical saline and / or solvate), followed by a second dose of about 300 mg of secfibetalistat (or its pharmaceutical saline and / or solvate), followed by a third dose of about 300 mg of secfibetalistat (or its pharmaceutical saline and / or solvate). mg of celefetrazol (or its pharmaceutical salt and / or solvate), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, and wherein the third dose is administered about 2 to about 6 hours after the second dose, preferably about 3 hours after the second dose, and wherein the prophylactic agent is selected from lanaleximab, berosalstat and C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert® or Haegarda®).
[0191] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering, on-demand, secfifeltistat (or its pharmaceutically acceptable saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the patient is given a first dose of about 300 mg of secfifeltistat (or its pharmaceutically acceptable saline and / or solvate), followed by a second dose of about 300 mg of secfifeltistat (or its pharmaceutically acceptable saline and / or solvate), followed by a third dose of about 300 mg of secfifeltistat (or its pharmaceutically acceptable saline and / or solvate), followed by a fourth dose of about 300 mg of secfifeltistat (or its pharmaceutically acceptable saline and / or solvate), and wherein the prophylactic agent is selected from lanaleximab, berositol, and C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®).
[0192] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: on-demand oral administration of secfithostat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the patient is given a first dose of about 300 mg of secfithostat (or its pharmaceutical saline and / or solvate), followed by a second dose of about 300 mg of secfithostat (or its pharmaceutical saline and / or solvate), followed by a third dose of about 300 mg of secfithostat (or its pharmaceutical saline and / or solvate), followed by a fourth dose of about 300 mg of secfithostat (or its pharmaceutical saline and / or solvate). mg of celefetrazol (or its pharmaceutical salt and / or solvate), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, wherein the third dose is administered about 2 to about 6 hours after the second dose, preferably about 3 hours after the second dose, and wherein the fourth dose is administered about 2 to about 6 hours after the third dose, preferably about 3 hours after the third dose, and wherein the prophylactic treatment agent is selected from lanalalimumab, berosalstat and C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert® or Haegarda®).
[0193] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, a first dose of approximately 300 mg of secfistat (or its pharmaceutically acceptable saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is selected from lanaleximab and berosstat.
[0194] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering secfifeltstat (or its pharmaceutically acceptable saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein a first dose of about 300 mg of secfifeltstat (or its pharmaceutically acceptable saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of secfifeltstat (or its pharmaceutically acceptable saline and / or solvate), wherein the prophylactic agent is selected from lanaleximab and berositstat.
[0195] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, secfifeltistat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein a first dose of about 300 mg of secfifeltistat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of secfifeltistat (or its pharmaceutical saline and / or solvate), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, and wherein the prophylactic agent is selected from lanaleximab and berositol.
[0196] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, secfifeltistat (or its pharmaceutically acceptable saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the patient is given a first dose of about 300 mg of secfifeltistat (or its pharmaceutically acceptable saline and / or solvate), followed by a second dose of about 300 mg of secfifeltistat (or its pharmaceutically acceptable saline and / or solvate), followed by a third dose of about 300 mg of secfifeltistat (or its pharmaceutically acceptable saline and / or solvate), and wherein the prophylactic agent is selected from lanaleximab and berositol.
[0197] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, oral celfiltrate statol (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the patient is given a first dose of about 300 mg of celfiltrate statol (or its pharmaceutical saline and / or solvate), followed by a second dose of about 300 mg of celfiltrate statol (or its pharmaceutical saline and / or solvate), followed by a third dose of about 300 mg of celfiltrate statol (or its pharmaceutical saline and / or solvate), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, and wherein the third dose is administered about 2 to about 6 hours after the second dose, preferably about 3 hours after the second dose, and wherein the prophylactic agent is selected from lanaleximab and berositol.
[0198] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, secfifestat (or its pharmaceutically acceptable saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the patient is given a first dose of about 300 mg of secfifestat (or its pharmaceutically acceptable saline and / or solvate), followed by a second dose of about 300 mg of secfifestat (or its pharmaceutically acceptable saline and / or solvate), followed by a third dose of about 300 mg of secfifestat (or its pharmaceutically acceptable saline and / or solvate), followed by a fourth dose of about 300 mg of secfifestat (or its pharmaceutically acceptable saline and / or solvate), and wherein the prophylactic agent is selected from lanaleximab and berositol.
[0199] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: on-demand oral administration of secfithostat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the patient is given a first dose of about 300 mg of secfithostat (or its pharmaceutical saline and / or solvate), followed by a second dose of about 300 mg of secfithostat (or its pharmaceutical saline and / or solvate), followed by a third dose of about 300 mg of secfithostat (or its pharmaceutical saline and / or solvate), followed by a fourth dose of about 300 mg of secfithostat (or its pharmaceutical saline and / or solvate). mg of celefetrazol (or its pharmaceutical salt and / or solvate), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, wherein the third dose is administered about 2 to about 6 hours after the second dose, preferably about 3 hours after the second dose, and wherein the fourth dose is administered about 2 to about 6 hours after the third dose, preferably about 3 hours after the third dose, and wherein the prophylactic agent is selected from lanalidomide and berositol.
[0200] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, a first dose of approximately 300 mg of secfistat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is lanaleximab.
[0201] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering secfibetalistat (or its pharmaceutically acceptable saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein a first dose of about 300 mg of secfibetalistat (or its pharmaceutically acceptable saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of secfibetalistat (or its pharmaceutically acceptable saline and / or solvate), wherein the prophylactic agent is lanaleximab.
[0202] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, celefatestat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein a first dose of about 300 mg of celefatestat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of celefatestat (or its pharmaceutical saline and / or solvate), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, and wherein the prophylactic agent is lanaleximab.
[0203] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, celefatestat (or its pharmaceutically acceptable saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the patient is given a first dose of about 300 mg of celefatestat (or its pharmaceutically acceptable saline and / or solvate), followed by a second dose of about 300 mg of celefatestat (or its pharmaceutically acceptable saline and / or solvate), followed by a third dose of about 300 mg of celefatestat (or its pharmaceutically acceptable saline and / or solvate), and wherein the prophylactic agent is lanaleximab.
[0204] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, celfiltratestat (or its pharmaceutical saponins and / or solvates) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the patient is given a first dose of about 300 mg of celfiltratestat (or its pharmaceutical saponins and / or solvates), followed by a second dose of about 300 mg of celfiltratestat (or its pharmaceutical saponins and / or solvates), followed by a third dose of about 300 mg of celfiltratestat (or its pharmaceutical saponins and / or solvates), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, and wherein the third dose is administered about 2 to about 6 hours after the second dose, preferably about 3 hours after the second dose, and wherein the prophylactic agent is lanaleximab.
[0205] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, celfiltratestat (or its pharmaceutically acceptable saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the patient is given a first dose of about 300 mg of celfiltratestat (or its pharmaceutically acceptable saline and / or solvate), followed by a second dose of about 300 mg of celfiltratestat (or its pharmaceutically acceptable saline and / or solvate), followed by a third dose of about 300 mg of celfiltratestat (or its pharmaceutically acceptable saline and / or solvate), followed by a fourth dose of about 300 mg of celfiltratestat (or its pharmaceutically acceptable saline and / or solvate), and wherein the prophylactic agent is lanaleximab.
[0206] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: on-demand oral administration of secfithostat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the patient is given a first dose of about 300 mg of secfithostat (or its pharmaceutical saline and / or solvate), followed by a second dose of about 300 mg of secfithostat (or its pharmaceutical saline and / or solvate), followed by a third dose of about 300 mg of secfithostat (or its pharmaceutical saline and / or solvate), followed by a fourth dose of about 300 mg of secfithostat (or its pharmaceutical saline and / or solvate). mg of celefetrazol (or its pharmaceutical salt and / or solvate), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, wherein the third dose is administered about 2 to about 6 hours after the second dose, preferably about 3 hours after the second dose, and wherein the fourth dose is administered about 2 to about 6 hours after the third dose, preferably about 3 hours after the third dose, and wherein the prophylactic therapeutic agent is lanalinoumab.
[0207] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on demand, a first dose of approximately 300 mg of secbetstatin (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is berosstatin.
[0208] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, secbetalstat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein a first dose of about 300 mg of secbetalstat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of secbetalstat (or its pharmaceutical saline and / or solvate), wherein the prophylactic agent is berositol.
[0209] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, oral secifetrestat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein a first dose of about 300 mg of secifetrestat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of secifetrestat (or its pharmaceutical saline and / or solvate), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, and wherein the prophylactic agent is berositol.
[0210] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, secbetalstat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the patient is given a first dose of about 300 mg of secbetalstat (or its pharmaceutical saline and / or solvate), followed by a second dose of about 300 mg of secbetalstat (or its pharmaceutical saline and / or solvate), followed by a third dose of about 300 mg of secbetalstat (or its pharmaceutical saline and / or solvate), and wherein the prophylactic agent is berositol.
[0211] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, oral selenostat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the patient is given a first dose of about 300 mg of selenostat (or its pharmaceutical saline and / or solvate), followed by a second dose of about 300 mg of selenostat (or its pharmaceutical saline and / or solvate), followed by a third dose of about 300 mg of selenostat (or its pharmaceutical saline and / or solvate), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, and wherein the third dose is administered about 2 to about 6 hours after the second dose, preferably about 3 hours after the second dose, and wherein the prophylactic agent is berositol.
[0212] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, secifetrestat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the patient is given a first dose of about 300 mg of secifetrestat (or its pharmaceutical saline and / or solvate), followed by a second dose of about 300 mg of secifetrestat (or its pharmaceutical saline and / or solvate), followed by a third dose of about 300 mg of secifetrestat (or its pharmaceutical saline and / or solvate), followed by a fourth dose of about 300 mg of secifetrestat (or its pharmaceutical saline and / or solvate), and wherein the prophylactic agent is berositol.
[0213] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: on-demand oral administration of secfithostat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the patient is given a first dose of about 300 mg of secfithostat (or its pharmaceutical saline and / or solvate), followed by a second dose of about 300 mg of secfithostat (or its pharmaceutical saline and / or solvate), followed by a third dose of about 300 mg of secfithostat (or its pharmaceutical saline and / or solvate), followed by a fourth dose of about 300 mg of secfithostat (or its pharmaceutical saline and / or solvate). mg of cefixime (or its pharmaceutical salt and / or solvate), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, wherein the third dose is administered about 2 to about 6 hours after the second dose, preferably about 3 hours after the second dose, and wherein the fourth dose is administered about 2 to about 6 hours after the third dose, preferably about 3 hours after the third dose, and wherein the prophylactic treatment agent is berositol.
[0214] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on demand, a first dose of approximately 300 mg of secbetasstat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic treatment for HAE, wherein the prophylactic treatment is a C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®).
[0215] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering secbetalstat (or its pharmaceutical saline and / or solvate) orally to a patient in need as needed, wherein the patient is also treated with a prophylactic agent for HAE, and wherein a first dose of about 300 mg of secbetalstat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of secbetalstat (or its pharmaceutical saline and / or solvate), wherein the prophylactic agent is a C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®).
[0216] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, oral selenostat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein a first dose of about 300 mg of selenostat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of selenostat (or its pharmaceutical saline and / or solvate), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, and wherein the prophylactic agent is a C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®).
[0217] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, orally to a patient in need secbetelstat (or its pharmaceutical saline and / or solvate), wherein the patient is also treated with a prophylactic agent for HAE, and wherein the patient is given a first dose of about 300 mg of secbetelstat (or its pharmaceutical saline and / or solvate), followed by a second dose of about 300 mg of secbetelstat (or its pharmaceutical saline and / or solvate), followed by a third dose of about 300 mg of secbetelstat (or its pharmaceutical saline and / or solvate), and wherein the prophylactic agent is a C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®).
[0218] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, oral selegiline statone (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the patient is given a first dose of about 300 mg of selegiline statone (or its pharmaceutical saline and / or solvate), followed by a second dose of about 300 mg of selegiline statone (or its pharmaceutical saline and / or solvate), followed by a third dose of about 300 mg of selegiline statone (or its pharmaceutical saline and / or solvate), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, and wherein the third dose is administered about 2 to about 6 hours after the second dose, preferably about 3 hours after the second dose, and wherein the prophylactic agent is a C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®).
[0219] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, selenostat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the patient is given a first dose of about 300 mg of selenostat (or its pharmaceutical saline and / or solvate), followed by a second dose of about 300 mg of selenostat (or its pharmaceutical saline and / or solvate), followed by a third dose of about 300 mg of selenostat (or its pharmaceutical saline and / or solvate), followed by a fourth dose of about 300 mg of selenostat (or its pharmaceutical saline and / or solvate), and wherein the prophylactic agent is a C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®).
[0220] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: on-demand oral administration of secfithostat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the patient is given a first dose of about 300 mg of secfithostat (or its pharmaceutical saline and / or solvate), followed by a second dose of about 300 mg of secfithostat (or its pharmaceutical saline and / or solvate), followed by a third dose of about 300 mg of secfithostat (or its pharmaceutical saline and / or solvate), followed by a fourth dose of about 300 mg of secfithostat (or its pharmaceutical saline and / or solvate). mg of seletestat (or its pharmaceutical salt and / or solvate), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, wherein the third dose is administered about 2 to about 6 hours after the second dose, preferably about 3 hours after the second dose, and wherein the fourth dose is administered about 2 to about 6 hours after the third dose, preferably about 3 hours after the third dose, and wherein the prophylactic treatment is a C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert® or Haegarda®).
[0221] In any of the above embodiments, the HAE seizure is selected from laryngeal seizures, neck and above seizures, abdominal seizures, subcutaneous seizures, arm seizures, hand seizures, leg seizures, foot seizures, head seizures, facial seizures, neck seizures, trunk seizures, and genital seizures. In one embodiment, the HAE seizure is a laryngeal seizure. In one embodiment, the HAE seizure is a neck and above seizure. In one embodiment, the HAE seizure is a neck and above seizure but not a laryngeal seizure. In one embodiment, the HAE seizure is an abdominal seizure. In one embodiment, the HAE seizure is a subcutaneous seizure. In one embodiment, the HAE seizure is an arm seizure. In one embodiment, the HAE seizure is a hand seizure. In one embodiment, the HAE seizure is a leg seizure. In one embodiment, the HAE seizure is a foot seizure. In one embodiment, the HAE seizure is a head seizure. In one embodiment, the HAE seizure is a facial seizure. In one embodiment, the HAE seizure is a neck seizure. In one embodiment, the HAE seizure is a trunk seizure. In one embodiment, the HAE seizure is a genital seizure.
[0222] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: on-demand oral administration of sevirate statol (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the patient is also treated with a prophylactic treatment agent for HAE, and wherein the HAE attack is a laryngeal attack.
[0223] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on demand, a first dose of about 300 mg of secbetstatin (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic treatment for HAE, and wherein the HAE attack is a laryngeal attack.
[0224] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on demand, a first dose of about 300 mg of secbetalstat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is berosstat and wherein the HAE attack is a laryngeal attack.
[0225] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on demand, a first dose of approximately 300 mg of secbetstastat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is lanaleximab and wherein the HAE attack is a laryngeal attack.
[0226] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on demand, a first dose of approximately 300 mg of secbetasstat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is a C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®) and wherein the HAE attack is a laryngeal attack.
[0227] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: on-demand oral administration of secfistat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the attack subsides without administration of a second dose to the patient. In one embodiment, the prophylactic agent is selected from lanaleximab, berositol, and C1INH replacement therapies (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®).
[0228] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering sevimetast (or its pharmaceutical saline and / or solvate) orally to a patient in need as needed, wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is lanaleximab and wherein the attack subsides without administration of a second dose to the patient.
[0229] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering selebuterol (or its pharmaceutical saline and / or solvate) orally to a patient in need as needed, wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is berosstat and wherein the attacks subside without administration of a second dose to the patient.
[0230] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering selebutatine (or its pharmaceutical saline and / or solvate) orally to a patient in need as needed, wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is a C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®) and wherein the attacks subside without administration of a second dose to the patient.
[0231] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on demand, a first dose of approximately 300 mg of secbetalstat (or its pharmaceutically acceptable saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the attack subsides without administration of a second dose to the patient. In one embodiment, the prophylactic agent is selected from lanaleximab, berosalstat, and C1INH replacement therapies (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®).
[0232] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, a first dose of approximately 300 mg of secbetstastat (or its pharmaceutically acceptable saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is lanaleximab and wherein the attacks subside without administration of a second dose to the patient.
[0233] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on demand, a first dose of about 300 mg of secbetalstat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is berosstat and wherein the attacks subside without administration of a second dose to the patient.
[0234] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on demand, a first dose of approximately 300 mg of secbetasstat (or its pharmaceutically acceptable saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is a C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®) and wherein the attacks subside without administration of a second dose to the patient.
[0235] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on demand, a first dose of about 300 mg of secbetalstat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic treatment agent for HAE, wherein the HAE attack is a laryngeal attack, and wherein the attack subsides without administration of a second dose to the patient.
[0236] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on demand, a first dose of about 300 mg of secbetalstat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic treatment for HAE, and wherein the HAE attacks occur in the neck and above.
[0237] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on demand, a first dose of about 300 mg of secbetalstat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic treatment for HAE, and wherein the HAE attack is an abdominal attack.
[0238] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering, as needed, an oral first dose of approximately 300 mg of secfistat (or its pharmaceutically acceptable saline and / or solvate) to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the HAE episode is a subcutaneous episode. In one embodiment, the prophylactic agent is selected from lanalalimumab, berosstat, and C1INH replacement therapies (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®).
[0239] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on demand, a first dose of about 300 mg of secbetalstat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is berosstat and wherein the HAE attack is a subcutaneous attack.
[0240] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering, on demand, a first dose of approximately 300 mg of secbetstastat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is lanaleximab and wherein the HAE episode is a subcutaneous episode.
[0241] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering, on demand, a first dose of approximately 300 mg of secbetasstat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is a C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®) and wherein the HAE episode is a subcutaneous episode.
[0242] In any of the above embodiments, a HAE seizure is characterized as "mild" or worse according to the PGI-S scale. In one embodiment, a HAE seizure is characterized as "mild" according to the PGI-S scale. In another embodiment, a HAE seizure is characterized as "moderate" or worse according to the PGI-S scale. In one embodiment, a HAE seizure is characterized as "moderate" according to the PGI-S scale. Preferably, a HAE seizure is characterized as "severe" or worse according to the PGI-S scale. In particular, a HAE seizure is characterized as "severe" or "extremely severe" according to the PGI-S scale.
[0243] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering, on demand, a first dose of approximately 300 mg of secbetalstat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and the HAE episode is characterized as “mild” or above according to the PGI-S scale.
[0244] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering, as needed, an oral first dose of approximately 300 mg of secfistat (or its pharmaceutically acceptable saline and / or solvate) to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and the HAE episode is characterized as “mild” according to the PGI-S scale. In one embodiment, the prophylactic agent is selected from lanaleximab, berositol, and C1INH replacement therapies (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®).
[0245] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering, on demand, a first dose of approximately 300 mg of secbetalstat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is berosalstat and the HAE episode is characterized as “mild” according to the PGI-S scale.
[0246] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering, on demand, a first dose of approximately 300 mg of secbetalstat (or its pharmaceutically acceptable saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is lanaleximab and the HAE episode is characterized as “mild” according to the PGI-S scale.
[0247] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering, on demand, a first dose of approximately 300 mg of secbetasstat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is a C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®) and the HAE episode is characterized as “mild” according to the PGI-S scale.
[0248] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering, on demand, a first dose of approximately 300 mg of secbetalstat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and the HAE episode is characterized as “moderate” or higher according to the PGI-S scale.
[0249] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: orally administering, as needed, a first dose of approximately 300 mg of secfistat (or its pharmaceutically acceptable saline and / or solvate) to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and the HAE episode is characterized as “moderate” according to the PGI-S scale. In one embodiment, the prophylactic agent is selected from lanaleximab, berositol, and C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®).
[0250] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering, on demand, a first dose of approximately 300 mg of secfistat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is berosstat and the HAE episode is characterized as “moderate” according to the PGI-S scale.
[0251] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering, on-demand, a first dose of approximately 300 mg of secfistat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is lanaleximab and the HAE episode is characterized as “moderate” according to the PGI-S scale.
[0252] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering, on demand, a first oral dose of approximately 300 mg of secbetasstat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is a C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®) and the HAE episode is characterized as “moderate” according to the PGI-S scale.
[0253] This invention provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: orally administering a first dose of approximately 300 mg of secfistat (or its pharmaceutically acceptable saline and / or solvate) to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the HAE attack is characterized as “severe” or worse according to the PGI-S scale. In one embodiment, the HAE attack is characterized as “severe” according to the PGI-S scale. In another embodiment, the HAE attack is characterized as “very severe” according to the PGI-S scale.
[0254] This invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: orally administering, as needed, a first dose of approximately 300 mg of secfistat (or its pharmaceutically acceptable saline and / or solvate) to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the HAE episode is characterized as “mild” or worse according to the PGI-S scale. In one embodiment, the HAE episode is characterized as “mild” according to the PGI-S scale.
[0255] This invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: orally administering a first dose of approximately 300 mg of secbetstatin (or its pharmaceutically acceptable saline and / or solvate) to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the HAE episode is characterized as “moderate” or higher according to the PGI-S scale. In one embodiment, the HAE episode is characterized as “moderate” according to the PGI-S scale.
[0256] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: on-demand oral administration of secfibetalistat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein a first dose of about 300 mg of secfibetalistat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of secfibetalistat (or its pharmaceutical saline and / or solvate), and wherein the HAE attack is characterized as “severe” or worse according to the PGI-S scale. In one embodiment, the HAE attack is characterized as “severe” according to the PGI-S scale. In another embodiment, the HAE attack is characterized as “very severe” according to the PGI-S scale.
[0257] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: on-demand oral administration of secfistat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein a first dose of about 300 mg of secfistat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of secfistat (or its pharmaceutical saline and / or solvate), and wherein the HAE episode is characterized as “mild” or worse according to the PGI-S scale. In one embodiment, the HAE episode is characterized as “mild” according to the PGI-S scale.
[0258] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering, on-demand, orally to a patient in need secbetalstat (or its pharmaceutical saline and / or solvate), wherein the patient is also treated with a prophylactic agent for HAE, and wherein a first dose of about 300 mg of secbetalstat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of secbetalstat (or its pharmaceutical saline and / or solvate), and wherein the HAE episode is characterized as “moderate” or higher according to the PGI-S scale. In one embodiment, the HAE episode is characterized as “moderate” according to the PGI-S scale.
[0259] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: orally administering, as needed, a first dose of approximately 300 mg of secbetstatin (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, wherein the HAE attack is a laryngeal attack, and wherein the HAE attack is characterized as “severe” or worse according to the PGI-S scale. In one embodiment, the HAE attack is characterized as “severe” according to the PGI-S scale. In another embodiment, the HAE attack is characterized as “very severe” according to the PGI-S scale.
[0260] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: orally administering a first dose of approximately 300 mg of secbetstatin (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, wherein the HAE episode is a laryngeal episode, wherein the HAE episode is characterized as “severe” or worse according to the PGI-S scale, and wherein the episode subsides without administration of a second dose to the patient. In one embodiment, the HAE episode is characterized as “severe” according to the PGI-S scale. In another embodiment, the HAE episode is characterized as “very severe” according to the PGI-S scale.
[0261] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on demand, a first dose of approximately 300 mg of secbetstatin (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, wherein the HAE attack is a laryngeal attack, and wherein the HAE attack is characterized as “mild” or worse according to the PGI-S scale. In one embodiment, the HAE attack is characterized as “mild” according to the PGI-S scale.
[0262] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering, on demand, a first dose of approximately 300 mg of secbetstatin (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, wherein the HAE episode is a laryngeal episode, wherein the HAE episode is characterized as “mild” or worse according to the PGI-S scale, and wherein the episode subsides without administration of a second dose to the patient. In one embodiment, the HAE episode is characterized as “mild” according to the PGI-S scale.
[0263] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on demand, a first dose of approximately 300 mg of secbetstatin (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, wherein the HAE attack is a laryngeal attack, and wherein the HAE attack is characterized as “moderate” or higher according to the PGI-S scale. In one embodiment, the HAE attack is characterized as “moderate” according to the PGI-S scale.
[0264] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on demand, a first dose of approximately 300 mg of secbetstatin (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, wherein the HAE attack is a laryngeal attack, wherein the HAE attack is characterized as “moderate” or higher according to the PGI-S scale, and wherein the attack subsides without administration of a second dose to the patient. In one embodiment, the HAE attack is characterized as “moderate” according to the PGI-S scale.
[0265] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: orally administering, as needed, a first dose of approximately 300 mg of secbetstatin (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, wherein the HAE attack is an attack in the neck or above, and wherein the HAE attack is characterized as “severe” or above according to the PGI-S scale. In one embodiment, the HAE attack is characterized as “severe” according to the PGI-S scale. In another embodiment, the HAE attack is characterized as “very severe” according to the PGI-S scale.
[0266] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on demand, a first dose of approximately 300 mg of secfistat (or its pharmaceutically acceptable saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, wherein the HAE attack is an attack in the neck or above, and wherein the HAE attack is characterized as “mild” or above according to the PGI-S scale. In one embodiment, the HAE attack is characterized as “mild” according to the PGI-S scale.
[0267] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on demand, a first dose of approximately 300 mg of secbetstatin (or its pharmaceutically acceptable saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, wherein the HAE attacks occur in the neck or above, and wherein the HAE attacks are characterized as “moderate” or higher according to the PGI-S scale. In one embodiment, the HAE attacks are characterized as “moderate” according to the PGI-S scale.
[0268] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: orally administering, as needed, a first dose of approximately 300 mg of secbetstatin (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the HAE attack is an abdominal attack, and wherein the HAE attack is characterized as “severe” or worse according to the PGI-S scale. In one embodiment, the HAE attack is characterized as “severe” according to the PGI-S scale. In another embodiment, the HAE attack is characterized as “very severe” according to the PGI-S scale.
[0269] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on demand, a first dose of approximately 300 mg of secbetstatin (or its pharmaceutically acceptable saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the HAE attack is an abdominal attack, and wherein the HAE attack is characterized as “mild” or worse according to the PGI-S scale. In one embodiment, the HAE attack is characterized as “mild” according to the PGI-S scale.
[0270] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on demand, a first dose of approximately 300 mg of secbetstatin (or its pharmaceutically acceptable saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the HAE attack is an abdominal attack, and wherein the HAE attack is characterized as “moderate” or higher according to the PGI-S scale. In one embodiment, the HAE attack is characterized as “moderate” according to the PGI-S scale.
[0271] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: orally administering, as needed, a first dose of approximately 300 mg of secbetstatin (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the HAE attack is a subcutaneous attack, and wherein the HAE attack is characterized as “severe” or worse according to the PGI-S scale. In one embodiment, the HAE attack is characterized as “severe” according to the PGI-S scale. In another embodiment, the HAE attack is characterized as “very severe” according to the PGI-S scale.
[0272] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on demand, a first dose of approximately 300 mg of secfistat (or its pharmaceutically acceptable saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the HAE attack is a subcutaneous attack, and wherein the HAE attack is characterized as “mild” or worse according to the PGI-S scale. In one embodiment, the HAE attack is characterized as “mild” according to the PGI-S scale.
[0273] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on demand, a first dose of approximately 300 mg of secbetstatin (or its pharmaceutically acceptable saline and / or solvate) orally to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the HAE attack is a subcutaneous attack, and wherein the HAE attack is characterized as “moderate” or higher according to the PGI-S scale. In one embodiment, the HAE attack is characterized as “moderate” according to the PGI-S scale.
[0274] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: orally administering, as needed, a first dose of approximately 300 mg of secbetstatin (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the HAE attack is an attack in the neck or above but not in the larynx, and wherein the HAE attack is characterized as “severe” or worse according to the PGI-S scale. In one embodiment, the HAE attack is characterized as “severe” according to the PGI-S scale. In another embodiment, the HAE attack is characterized as “very severe” according to the PGI-S scale.
[0275] Medication
[0276] Given the severity of HAE attacks, and their potential to escalate to the point of being life-threatening, it is crucial that any on-demand treatment provides reliable, safe, and effective care. The data in Example 4 further confirm that the specific dosing regimen of secbetstastat provides such reliable treatment.
[0277] Therefore, the present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering secbetalstat (or its pharmaceutical saline and / or solvate) orally to a patient in need as needed, wherein a first dose of about 300 mg of secbetalstat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of secbetalstat (or its pharmaceutical saline and / or solvate).
[0278] For the avoidance of doubt, any of the embodiments described above regarding the treatment of severe or more serious HAE attacks according to the present invention, or regarding the treatment of HAE attacks in patients receiving prophylactic treatment, or the following regarding the treatment of HAE attacks in the neck and above, specific combination therapies, and drug-drug interactions, may be considered for combination with any of the embodiments described herein regarding medication, where appropriate. It is intended that any of these embodiments may be combined. Specific embodiments are shown below.
[0279] Specific medication regimen
[0280] In one embodiment, the first dose is administered as needed within approximately 1 hour of recognizing symptoms of an acute HAE attack. In another embodiment, the first dose is administered as needed within approximately 50 minutes, approximately 40 minutes, approximately 30 minutes, approximately 20 minutes, approximately 10 minutes, approximately 6 minutes, or approximately 5 minutes of recognizing symptoms of an acute HAE attack.
[0281] In one embodiment, the second dose is administered about 2 hours to about 6 hours after the first dose (more specifically, about 2 hours to about 5 hours, about 2 hours to about 4 hours, or 2 hours to about 3 hours). Preferably, the second dose is administered about 3 hours after the first dose.
[0282] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering secbetalstat (or its pharmaceutical saponins and / or solvates) orally to a patient in need as required, wherein a first dose of about 300 mg of secbetalstat (or its pharmaceutical saponins and / or solvates) is administered to the patient, followed by a second dose of about 300 mg of secbetalstat (or its pharmaceutical saponins and / or solvates), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose.
[0283] In one embodiment, the third dose is not administered to the patient, for example, if the first and second doses provide sufficient therapeutic efficacy, such as the attack subsiding without the third dose being administered. In an alternative embodiment, the patient is given a third dose of about 300 mg of secbestat (or its pharmaceutically acceptable saline and / or solvate). The third dose may be administered about 2 hours to about 6 hours after the second dose (more specifically, about 2 hours to about 5 hours, about 2 hours to about 4 hours, or 2 hours to about 3 hours). Preferably, the third dose may be administered about 3 hours after the second dose.
[0284] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering secbetalstat (or its pharmaceutical saponins and / or solvates) orally to a patient in need as needed, wherein a first dose of about 300 mg of secbetalstat (or its pharmaceutical saponins and / or solvates) is administered to the patient, followed by a second dose of about 300 mg of secbetalstat (or its pharmaceutical saponins and / or solvates), followed by a third dose of about 300 mg of secbetalstat (or its pharmaceutical saponins and / or solvates).
[0285] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering seftiofruct (or its pharmaceutical saponins and / or solvates) orally to a patient in need as needed, wherein a first dose of about 300 mg of seftiofruct (or its pharmaceutical saponins and / or solvates) is administered to the patient, followed by a second dose of about 300 mg of seftiofruct (or its pharmaceutical saponins and / or solvates), followed by a third dose of about 300 mg of seftiofruct (or its pharmaceutical saponins and / or solvates), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, and wherein the third dose is administered about 2 to about 6 hours after the second dose, preferably about 3 hours after the second dose.
[0286] In one embodiment, a fourth dose is not administered to the patient, for example, if the first, second, and third doses provide sufficient therapeutic efficacy, such as the attack subsiding without the fourth dose being administered. In an alternative embodiment, a fourth dose of about 300 mg of secbestat (or its pharmaceutically acceptable saline and / or solvate) is administered to the patient. The fourth dose may be administered about 2 hours to about 6 hours after the third dose (more specifically, about 2 hours to about 5 hours, about 2 hours to about 4 hours, or 2 hours to about 3 hours). Preferably, the fourth dose may be administered about 3 hours after the third dose.
[0287] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering secbetalstat (or its pharmaceutical saline and / or solvate) orally to a patient in need as required, wherein a first dose of about 300 mg of secbetalstat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of secbetalstat (or its pharmaceutical saline and / or solvate), followed by a third dose of about 300 mg of secbetalstat (or its pharmaceutical saline and / or solvate), followed by a fourth dose of about 300 mg of secbetalstat (or its pharmaceutical saline and / or solvate).
[0288] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, selenostat (or its pharmaceutical saponins and / or solvates) orally to a patient in need, wherein a first dose of about 300 mg of selenostat (or its pharmaceutical saponins and / or solvates) is administered to the patient, followed by a second dose of about 300 mg of selenostat (or its pharmaceutical saponins and / or solvates), followed by a third dose of about 300 mg of selenostat (or its pharmaceutical saponins and / or solvates), followed by a fourth dose of about 300 mg of selenostat (or its pharmaceutical saponins and / or solvates), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, wherein the third dose is administered about 2 to about 6 hours after the second dose, preferably about 3 hours after the second dose, and wherein the fourth dose is administered about 2 to about 6 hours after the third dose, preferably about 3 hours after the third dose.
[0289] In one implementation, no further dose is administered to the patient, for example, the attack subsides without any further dose being administered to the patient, particularly without a fifth dose.
[0290] In any of the above embodiments, each dose is preferably administered as a unit dose. In particular, each unit dose is preferably administered as a tablet (e.g., a film-coated tablet or an orally disintegrating tablet).
[0291] In any of the implementation schemes described herein, the patient may also be receiving treatment with a prophylactic agent of HAE. Specific implementation schemes in which the patient is also receiving treatment with a prophylactic agent of HAE are described above.
[0292] In any of the above implementation schemes, the prophylactic treatment for HAE may be a PKa binder, a bradykinin B2 receptor antagonist, a factor XIIa (FXIIa) binder, or a C1INH substitute.
[0293] Prophylactic treatment for HAE can be a pKa binder, preferably a plasma kallikrein inhibitor.
[0294] Prophylactic treatment for HAE can be bradykinin B2 receptor antagonists.
[0295] Prophylactic treatment for HAE can be factor XIIa (FXIIa) binders, preferably FXIIa inhibitors.
[0296] Prophylactic treatment for HAE can be a reduced-dose androgen. Specifically, a reduced-dose androgen can be danazol or oxandrolone. Prophylactic treatment for HAE can also be tranexamic acid. Alternatively, prophylactic treatment for HAE can be non-androgen therapy.
[0297] Prophylactic agents for HAE may be selected from lanazalimumab, dadaxisab, berositol, STAR 0215, C1INH replacement therapies (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®), donidalosin, and deucrictibant. In one embodiment, the prophylactic agent is selected from dadaxisab, STAR 0215, C1INH replacement therapies (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®), donidalosin, and deucrictibant.
[0298] In another implementation, the prophylactic treatment for HAE is a C1 inhibitor. Specifically, the prophylactic treatment may be Cinryze®, Haegarda®, or Berinert®.
[0299] Prophylactic treatments may include lanalidomide or berositol.
[0300] Prophylactic treatment may include lanalidomide.
[0301] Berosstat can be used as a preventative treatment.
[0302] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering secbetalstat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the patient has not been treated with a prophylactic agent for HAE, and wherein a first dose of about 300 mg of secbetalstat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of secbetalstat (or its pharmaceutical saline and / or solvate).
[0303] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, secbetalstat (or its pharmaceutical saponins and / or solvates) orally to a patient in need, wherein the patient has not been treated with a prophylactic agent for HAE, and wherein a first dose of about 300 mg of secbetalstat (or its pharmaceutical saponins and / or solvates) is administered to the patient, followed by a second dose of about 300 mg of secbetalstat (or its pharmaceutical saponins and / or solvates), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose.
[0304] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, orally secifexorstat (or its pharmaceutically acceptable saline and / or solvate) to a patient in need, wherein the patient has not been treated with a prophylactic agent for HAE, and wherein a first dose of about 300 mg of secifexorstat (or its pharmaceutically acceptable saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of secifexorstat (or its pharmaceutically acceptable saline and / or solvate), followed by a third dose of about 300 mg of secifexorstat (or its pharmaceutically acceptable saline and / or solvate).
[0305] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, seftiofruct (or its pharmaceutical saponins and / or solvates) orally to a patient in need, wherein the patient has not been treated with a prophylactic agent for HAE, and wherein a first dose of about 300 mg of seftiofruct (or its pharmaceutical saponins and / or solvates) is administered to the patient, followed by a second dose of about 300 mg of seftiofruct (or its pharmaceutical saponins and / or solvates), followed by a third dose of about 300 mg of seftiofruct (or its pharmaceutical saponins and / or solvates), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, and wherein the third dose is administered about 2 to about 6 hours after the second dose, preferably about 3 hours after the second dose.
[0306] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, secifetrestat (or its pharmaceutically acceptable saline and / or solvate) orally to a patient in need, wherein the patient has not been treated with a prophylactic agent for HAE, and wherein the patient is given a first dose of about 300 mg of secifetrestat (or its pharmaceutically acceptable saline and / or solvate), followed by a second dose of about 300 mg of secifetrestat (or its pharmaceutically acceptable saline and / or solvate), followed by a third dose of about 300 mg of secifetrestat (or its pharmaceutically acceptable saline and / or solvate), followed by a fourth dose of about 300 mg of secifetrestat (or its pharmaceutically acceptable saline and / or solvate).
[0307] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: on-demand oral administration of secfithostat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the patient has not been treated with a prophylactic agent for HAE, and wherein the patient is given a first dose of about 300 mg of secfithostat (or its pharmaceutical saline and / or solvate), followed by a second dose of about 300 mg of secfithostat (or its pharmaceutical saline and / or solvate), followed by a third dose of about 300 mg of secfithostat (or its pharmaceutical saline and / or solvate), followed by a fourth dose of about 300 mg of secfithostat (or its pharmaceutical saline and / or solvate). mg of seletestat (or its pharmaceutical salt and / or solvate), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, wherein the third dose is administered about 2 to about 6 hours after the second dose, preferably about 3 hours after the second dose, and wherein the fourth dose is administered about 2 to about 6 hours after the third dose, preferably about 3 hours after the third dose.
[0308] In any of the above embodiments, the HAE seizure is selected from laryngeal seizures, neck and above seizures, abdominal seizures, subcutaneous seizures, arm seizures, hand seizures, leg seizures, foot seizures, head seizures, facial seizures, neck seizures, trunk seizures, and genital seizures. In one embodiment, the HAE seizure is a laryngeal seizure. In one embodiment, the HAE seizure is a neck and above seizure. In one embodiment, the HAE seizure is a neck and above seizure but not a laryngeal seizure. In one embodiment, the HAE seizure is an abdominal seizure. In one embodiment, the HAE seizure is a subcutaneous seizure. In one embodiment, the HAE seizure is an arm seizure. In one embodiment, the HAE seizure is a hand seizure. In one embodiment, the HAE seizure is a leg seizure. In one embodiment, the HAE seizure is a foot seizure. In one embodiment, the HAE seizure is a head seizure. In one embodiment, the HAE seizure is a facial seizure. In one embodiment, the HAE seizure is a neck seizure. In one embodiment, the HAE seizure is a trunk seizure. In one embodiment, the HAE seizure is a genital seizure.
[0309] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: on-demand oral administration of secfistat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein a first dose of about 300 mg of secfistat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by administration of a second dose of about 300 mg of secfistat (or its pharmaceutical saline and / or solvate), and wherein the HAE attack is a laryngeal attack.
[0310] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: on-demand oral administration of secfistat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein a first dose of about 300 mg of secfistat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by administration of a second dose of about 300 mg of secfistat (or its pharmaceutical saline and / or solvate), and wherein the HAE attack is an abdominal attack.
[0311] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: on-demand oral administration of secfistat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein a first dose of about 300 mg of secfistat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by administration of a second dose of about 300 mg of secfistat (or its pharmaceutical saline and / or solvate), and wherein the HAE episode is a subcutaneous episode.
[0312] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: on-demand oral administration of secbetalstat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein a first dose of about 300 mg of secbetalstat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by administration of a second dose of about 300 mg of secbetalstat (or its pharmaceutical saline and / or solvate), wherein the second dose is administered about 2 hours to about 6 hours after the first dose, preferably about 3 hours after the first dose, and wherein the HAE attack is a laryngeal attack.
[0313] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: on-demand oral administration of secfistat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein a first dose of about 300 mg of secfistat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by administration of a second dose of about 300 mg of secfistat (or its pharmaceutical saline and / or solvate), wherein the second dose is administered about 2 hours to about 6 hours after the first dose, preferably about 3 hours after the first dose, and wherein the HAE attack is an abdominal attack.
[0314] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: on-demand oral administration of secfistat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein a first dose of about 300 mg of secfistat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by administration of a second dose of about 300 mg of secfistat (or its pharmaceutical saline and / or solvate), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, and wherein the HAE attack is a subcutaneous attack.
[0315] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: on-demand oral administration of secfistat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein a first dose of about 300 mg of secfistat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by administration of a second dose of about 300 mg of secfistat (or its pharmaceutical saline and / or solvate), followed by administration of a third dose of about 300 mg of secfistat (or its pharmaceutical saline and / or solvate), and wherein the HAE attack is a laryngeal attack.
[0316] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: on-demand oral administration of secfistat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein a first dose of about 300 mg of secfistat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by administration of a second dose of about 300 mg of secfistat (or its pharmaceutical saline and / or solvate), followed by administration of a third dose of about 300 mg of secfistat (or its pharmaceutical saline and / or solvate), and wherein the HAE attack is an abdominal attack.
[0317] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: on-demand oral administration of secfistat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein a first dose of about 300 mg of secfistat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by administration of a second dose of about 300 mg of secfistat (or its pharmaceutical saline and / or solvate), followed by administration of a third dose of about 300 mg of secfistat (or its pharmaceutical saline and / or solvate), and wherein the HAE episode is a subcutaneous episode.
[0318] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, selenostat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein a first dose of about 300 mg of selenostat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of selenostat (or its pharmaceutical saline and / or solvate), followed by a third dose of about 300 mg of selenostat (or its pharmaceutical saline and / or solvate), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, wherein the third dose is administered about 2 to about 6 hours after the second dose, preferably about 3 hours after the second dose, and wherein the HAE attack is a laryngeal attack.
[0319] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: on-demand oral administration of secfistat (or its pharmaceutical saponins and / or solvates) to a patient in need, wherein a first dose of about 300 mg of secfistat (or its pharmaceutical saponins and / or solvates) is administered to the patient, followed by a second dose of about 300 mg of secfistat (or its pharmaceutical saponins and / or solvates), followed by a third dose of about 300 mg of secfistat (or its pharmaceutical saponins and / or solvates), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, wherein the third dose is administered about 2 to about 6 hours after the second dose, preferably about 3 hours after the second dose, and wherein the HAE attack is an abdominal attack.
[0320] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: on-demand oral administration of secfistat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein a first dose of about 300 mg of secfistat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by administration of a second dose of about 300 mg of secfistat (or its pharmaceutical saline and / or solvate), followed by administration of a third dose of about 300 mg of secfistat (or its pharmaceutical saline and / or solvate), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, wherein the third dose is administered about 2 to about 6 hours after the second dose, preferably about 3 hours after the second dose, and wherein the HAE attack is a subcutaneous attack.
[0321] In any of the above embodiments, a HAE seizure is characterized as "mild" or worse according to the PGI-S scale. In one embodiment, a HAE seizure is characterized as "mild" according to the PGI-S scale. In another embodiment, a HAE seizure is characterized as "moderate" or worse according to the PGI-S scale. In one embodiment, a HAE seizure is characterized as "moderate" according to the PGI-S scale. Preferably, a HAE seizure is characterized as "severe" or worse according to the PGI-S scale. In particular, a HAE seizure is characterized as "severe" or "extremely severe" according to the PGI-S scale.
[0322] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: on-demand oral administration of secfistat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein a first dose of about 300 mg of secfistat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by administration of a second dose of about 300 mg of secfistat (or its pharmaceutical saline and / or solvate), and wherein the HAE episode is characterized as “mild” or worse according to the PGI-S scale.
[0323] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering secbetalstat (or its pharmaceutical saline and / or solvate) orally to a patient in need as needed, wherein a first dose of about 300 mg of secbetalstat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of secbetalstat (or its pharmaceutical saline and / or solvate), and wherein the HAE episode is characterized as “mild” according to the PGI-S scale.
[0324] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering secfifestat (or its pharmaceutical saline and / or solvate) orally to a patient in need as needed, wherein a first dose of about 300 mg of secfifestat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of secfifestat (or its pharmaceutical saline and / or solvate), and wherein the HAE episode is characterized as “moderate” or higher according to the PGI-S scale.
[0325] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering secbetalstat (or its pharmaceutical saline and / or solvate) orally to a patient in need as needed, wherein a first dose of about 300 mg of secbetalstat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of secbetalstat (or its pharmaceutical saline and / or solvate), and wherein the HAE episode is characterized as “moderate” according to the PGI-S scale.
[0326] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: on-demand oral administration of secfistat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein a first dose of about 300 mg of secfistat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by administration of a second dose of about 300 mg of secfistat (or its pharmaceutical saline and / or solvate), wherein the HAE episode is a laryngeal episode, and wherein the HAE episode is characterized as “mild” or worse according to the PGI-S scale.
[0327] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: on-demand oral administration of secfistat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein a first dose of about 300 mg of secfistat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by administration of a second dose of about 300 mg of secfistat (or its pharmaceutical saline and / or solvate), wherein the HAE attack is an abdominal attack, and wherein the HAE attack is characterized as “mild” or worse according to the PGI-S scale.
[0328] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: on-demand oral administration of secfistat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein a first dose of about 300 mg of secfistat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by administration of a second dose of about 300 mg of secfistat (or its pharmaceutical saline and / or solvate), wherein the HAE episode is a subcutaneous episode, and wherein the HAE episode is characterized as “mild” or worse according to the PGI-S scale.
[0329] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: on-demand oral administration of secfistat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein a first dose of about 300 mg of secfistat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by administration of a second dose of about 300 mg of secfistat (or its pharmaceutical saline and / or solvate), wherein the HAE episode is a laryngeal episode, and wherein the HAE episode is characterized as “moderate” or higher according to the PGI-S scale.
[0330] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: on-demand oral administration of secfistat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein a first dose of about 300 mg of secfistat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by administration of a second dose of about 300 mg of secfistat (or its pharmaceutical saline and / or solvate), wherein the HAE attack is an abdominal attack, and wherein the HAE attack is characterized as “moderate” or higher according to the PGI-S scale.
[0331] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering secfifeltstat (or its pharmaceutical saline and / or solvate) orally to a patient in need as needed, wherein a first dose of about 300 mg of secfifeltstat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of secfifeltstat (or its pharmaceutical saline and / or solvate), wherein the HAE episode is a subcutaneous episode, and wherein the HAE episode is characterized as “moderate” or higher according to the PGI-S scale.
[0332] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: on-demand oral administration of secfistat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein a first dose of about 300 mg of secfistat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by administration of a second dose of about 300 mg of secfistat (or its pharmaceutical saline and / or solvate), wherein the HAE episode is a laryngeal episode, and wherein the HAE episode is characterized as “severe” or worse according to the PGI-S scale.
[0333] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: on-demand oral administration of secfistat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein a first dose of about 300 mg of secfistat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by administration of a second dose of about 300 mg of secfistat (or its pharmaceutical saline and / or solvate), wherein the HAE attack is an abdominal attack, and wherein the HAE attack is characterized as “severe” or worse according to the PGI-S scale.
[0334] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: on-demand oral administration of secfistat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein a first dose of about 300 mg of secfistat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by administration of a second dose of about 300 mg of secfistat (or its pharmaceutical saline and / or solvate), wherein the HAE episode is a subcutaneous episode, and wherein the HAE episode is characterized as “severe” or worse according to the PGI-S scale.
[0335] Treatment of HAE attacks in the neck and above
[0336] As noted above, patients with HAE experience unpredictable and often disabling episodes of tissue swelling that can affect any part of the body and are particularly severe if the upper respiratory tract is involved. HAE episodes originating in the neck and above can lead to laryngeal attacks, which can be life-threatening if left untreated. Therefore, it is crucial that on-demand treatment of neck and above episodes is effective. In particular, treatment must be rapid and provide early intervention to shorten the duration and severity of episodes and lead to faster resolution. Barriers associated with current on-demand parenteral therapies mean that patients often delay treatment, and therefore there is an ongoing need to reassure patients that alternative (i.e., non-injectable) therapies will provide effective treatment for neck and above episodes.
[0337] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on demand, a first dose of about 300 mg of secbetalstat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the HAE attack is an attack in the neck or above.
[0338] For the avoidance of doubt, any of the above-described embodiments for treating severe or more serious HAE episodes, treating HAE episodes in patients receiving prophylactic treatment, or medication, or any of the embodiments described below regarding specific combination therapies and drug-drug interactions, may be considered in combination with any of the embodiments described herein for treating HAE episodes in the neck and above, where appropriate. It is intended that any of these embodiments may be combined.
[0339] Therefore, any of the treatments described herein can be used to treat HAE episodes in the neck and above, where appropriate. Specific implementation methods are shown below.
[0340] Specific treatment for HAE attacks in the neck and above
[0341] Seizures in the neck and above can be facial seizures (i.e., facial attacks) and / or tongue seizures and / or throat seizures. Seizures in the neck and above can be facial seizures. Seizures in the neck and above can be tongue seizures. Seizures in the neck and above can be throat seizures. Seizures in the neck and above can be laryngeal seizures. Seizures in the neck and above can be throat and / or tongue and / or facial seizures. Seizures in the neck and above can be tongue and / or throat and / or facial seizures. Seizures in the neck and above can be facial and / or throat and / or throat seizures. Seizures in the neck and above are throat seizures, but not laryngeal seizures.
[0342] In any of the above embodiments, the first dose may be administered as needed within one hour of recognizing symptoms of an acute HAE attack. In another embodiment, the first dose may be administered as needed within approximately 50 minutes, approximately 40 minutes, approximately 30 minutes, approximately 20 minutes, approximately 10 minutes, approximately 6 minutes, or approximately 5 minutes of recognizing symptoms of an acute HAE attack. In one embodiment, a second dose is not administered to the patient, for example, if the first dose provides sufficient therapeutic efficacy, such as if the attack can subside without the administration of a second dose.
[0343] In one implementation, attacks in the neck and above are laryngeal attacks and subside without the administration of a second dose to the patient.
[0344] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on demand, a first dose of about 300 mg of celefatestat (or its pharmaceutical salt and / or solvate) orally to a patient in need, wherein the HAE attack is an attack in the neck or above, wherein the attack in the neck or above is a laryngeal attack and the attack subsides without administration of a second dose to the patient.
[0345] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: on-demand oral administration of secfistat (or its pharmaceutically acceptable saline and / or solvate) to a patient in need, wherein the HAE attack is an attack in the neck or above, and wherein a first dose of about 300 mg of secfistat (or its pharmaceutically acceptable saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of secfistat (or its pharmaceutically acceptable saline and / or solvate). In one embodiment, the second dose is administered about 2 hours to about 6 hours after the first dose (more specifically, about 2 hours to about 5 hours, about 2 hours to about 4 hours, 2 hours to about 3 hours). Preferably, the second dose is administered about 3 hours after the first dose.
[0346] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, secifetrestat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the HAE attack is an attack in the neck or above, and wherein a first dose of about 300 mg of secifetrestat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of secifetrestat (or its pharmaceutical saline and / or solvate), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose.
[0347] In one embodiment, the third dose is not administered to the patient, for example, if the first and second doses provide sufficient therapeutic efficacy, such as the attack subsiding without the third dose being administered. In an alternative embodiment, the patient is given a third dose of about 300 mg of secbestat (or its pharmaceutically acceptable saline and / or solvate). The third dose may be administered about 2 hours to about 6 hours after the second dose (more specifically, about 2 hours to about 5 hours, about 2 hours to about 4 hours, or 2 hours to about 3 hours). Preferably, the third dose may be administered about 3 hours after the second dose.
[0348] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering celefatestat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the HAE attack is an attack in the neck or above, and wherein a first dose of about 300 mg of celefatestat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of celefatestat (or its pharmaceutical saline and / or solvate), followed by a third dose of about 300 mg of celefatestat (or its pharmaceutical saline and / or solvate).
[0349] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, seftiofur (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the HAE attack is an attack in the neck or above, and wherein a first dose of about 300 mg of seftiofur (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of seftiofur (or its pharmaceutical saline and / or solvate), followed by a third dose of about 300 mg of seftiofur (or its pharmaceutical saline and / or solvate), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, and wherein the third dose is administered about 2 to about 6 hours after the second dose, preferably about 3 hours after the second dose.
[0350] In one embodiment, a fourth dose is not administered to the patient, for example, if the first, second, and third doses provide sufficient therapeutic efficacy, such as the attack subsiding without the fourth dose being administered. In an alternative embodiment, a fourth dose of about 300 mg of secbestat (or its pharmaceutically acceptable saline and / or solvate) is administered to the patient. The fourth dose may be administered about 2 hours to about 6 hours after the third dose (more specifically, about 2 hours to about 5 hours, about 2 hours to about 4 hours, or 2 hours to about 3 hours). Preferably, the fourth dose may be administered about 3 hours after the third dose.
[0351] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, secifetrestat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the HAE attack is an attack in the neck or above, and wherein the patient is given a first dose of about 300 mg of secifetrestat (or its pharmaceutical saline and / or solvate), followed by a second dose of about 300 mg of secifetrestat (or its pharmaceutical saline and / or solvate), followed by a third dose of about 300 mg of secifetrestat (or its pharmaceutical saline and / or solvate), followed by a fourth dose of about 300 mg of secifetrestat (or its pharmaceutical saline and / or solvate).
[0352] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: on-demand oral administration of secfibetalistat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the HAE attack is an attack in the neck or above, and wherein the patient is given a first dose of about 300 mg of secfibetalistat (or its pharmaceutical saline and / or solvate), followed by a second dose of about 300 mg of secfibetalistat (or its pharmaceutical saline and / or solvate), followed by a third dose of about 300 mg of secfibetalistat (or its pharmaceutical saline and / or solvate), followed by a fourth dose of about 300 mg of secfibetalistat (or its pharmaceutical saline and / or solvate). mg of seletestat (or its pharmaceutical salt and / or solvate), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, wherein the third dose is administered about 2 to about 6 hours after the second dose, preferably about 3 hours after the second dose, and wherein the fourth dose is administered about 2 to about 6 hours after the third dose, preferably about 3 hours after the third dose.
[0353] In one implementation, no further dose is administered to the patient, for example, the attack subsides without any further dose being administered to the patient.
[0354] In any of the above embodiments, each dose is preferably administered as a unit dose. In particular, each unit dose is preferably administered as a tablet (e.g., a film-coated tablet or an orally disintegrating tablet).
[0355] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on demand, a first dose of about 300 mg of celefetrazol (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the HAE attack is an attack in the neck or above, and wherein the patient is also treated with a prophylactic agent for HAE.
[0356] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering secfibetalistat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the HAE attack is an attack in the neck or above, and wherein the patient is given a first dose of about 300 mg of secfibetalistat (or its pharmaceutical saline and / or solvate), followed by a second dose of about 300 mg of secfibetalistat (or its pharmaceutical saline and / or solvate), and wherein the patient is also treated with a prophylactic agent for HAE.
[0357] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, seftiofur (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the HAE attack is an attack in the neck or above, and wherein a first dose of about 300 mg of seftiofur (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of seftiofur (or its pharmaceutical saline and / or solvate), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, and wherein the patient is also treated with a prophylactic agent for HAE.
[0358] In any of the above implementation schemes, the prophylactic treatment for HAE may be a PKa binder, a bradykinin B2 receptor antagonist, a factor XIIa (FXIIa) binder, or a C1INH substitute.
[0359] Prophylactic treatment for HAE can be a pKa binder, preferably a plasma kallikrein inhibitor.
[0360] Prophylactic treatment for HAE can be bradykinin B2 receptor antagonists.
[0361] Prophylactic treatment for HAE can be factor XIIa (FXIIa) binders, preferably FXIIa inhibitors.
[0362] Prophylactic treatment for HAE can be a reduced-dose androgen. Specifically, a reduced-dose androgen can be danazol or oxandrolone. Prophylactic treatment for HAE can also be tranexamic acid. Alternatively, prophylactic treatment for HAE can be non-androgen therapy.
[0363] Prophylactic agents for HAE may be selected from lanazalimumab, dadaxisab, berositol, STAR 0215, C1INH replacement therapies (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®), donidalosin, and deucrictibant. In one embodiment, the prophylactic agent is selected from dadaxisab, STAR 0215, C1INH replacement therapies (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®), donidalosin, and deucrictibant.
[0364] In another implementation, the prophylactic treatment for HAE is a C1 inhibitor. Specifically, the prophylactic treatment may be Cinryze®, Haegarda®, or Berinert®.
[0365] Prophylactic treatments may include lanalidomide or berositol.
[0366] Prophylactic treatment may include lanalidomide.
[0367] Berosstat can be used as a preventative treatment.
[0368] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, a first dose of approximately 300 mg of secbetstatin (or its pharmaceutically acceptable saline and / or solvate) orally to a patient in need, wherein the HAE attack is an attack in the neck or above, and wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is a plasma kallikrein inhibitor.
[0369] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, oral secifettostat (or its pharmaceutically acceptable saline and / or solvate) to a patient in need, wherein the HAE attack is an attack in the neck or above, and wherein the patient is given a first dose of about 300 mg of secifettostat (or its pharmaceutically acceptable saline and / or solvate), followed by a second dose of about 300 mg of secifettostat (or its pharmaceutically acceptable saline and / or solvate), and wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is a plasma kallikrein inhibitor.
[0370] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, oral secifexitstat (or its pharmaceutically acceptable saline and / or solvate) to a patient in need, wherein the HAE attack is an attack in the neck or above, and wherein the patient is given a first dose of about 300 mg of secifexitstat (or its pharmaceutically acceptable saline and / or solvate), followed by a second dose of about 300 mg of secifexitstat (or its pharmaceutically acceptable saline and / or solvate), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, and wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is a plasma kallikrein inhibitor.
[0371] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: orally administering, as needed, a first dose of approximately 300 mg of secfistat (or its pharmaceutically acceptable saline and / or solvate) to a patient in need, wherein the HAE attack is an attack in the neck or above, and wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is selected from lanaleximab, gardacrumb, berositol, STAR 0215, C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®), donidalosin, and deucrictibant. In one embodiment, the prophylactic agent is selected from gardacrumb, STAR 0215, C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®), donidalosin, and deucrictibant.
[0372] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, orally secifexit statone (or its pharmaceutically acceptable saline and / or solvate) to a patient in need, wherein the HAE attack is an attack in the neck or above, and wherein the patient is given a first dose of about 300 mg of secifexit statone (or its pharmaceutically acceptable saline and / or solvate), followed by a second dose of about 300 mg of secifexit statone (or its pharmaceutically acceptable saline and / or solvate), and wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is selected from lanaleximab, caldacron, berostitone, STAR 0215, C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®), donidalosin, and deucrictibant. In one implementation, the prophylactic treatment agent is selected from dadaximab, STAR 0215, C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert® or Haegarda®), donidalosin, and deucrictibant.
[0373] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: on-demand oral administration of secfibetalistat (or its pharmaceutically acceptable saline and / or solvate) to a patient in need, wherein the HAE attack is an attack in the neck or above, and wherein a first dose of about 300 mg of secfibetalistat (or its pharmaceutically acceptable saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of secfibetalistat (or its pharmaceutically acceptable saline and / or solvate), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, and wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is selected from lanaleximab, caldacron, berositol, STAR 0215, C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®), donidalosin, and deucrictibant. In one implementation, the prophylactic treatment agent is selected from dadaximab, STAR 0215, C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert® or Haegarda®), donidalosin, and deucrictibant.
[0374] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering, on-demand, a first dose of approximately 300 mg of secfistat (or its pharmaceutically acceptable saline and / or solvate) orally to a patient in need, wherein the HAE episode is an episode occurring in the neck or above, and wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is selected from lanaleximab, berositol, and C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®).
[0375] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering, on-demand, oral secifetrestat (or its pharmaceutically acceptable saline and / or solvate) to a patient in need, wherein the HAE episode is an episode in the neck or above, and wherein the patient is given a first dose of about 300 mg of secifetrestat (or its pharmaceutically acceptable saline and / or solvate), followed by a second dose of about 300 mg of secifetrestat (or its pharmaceutically acceptable saline and / or solvate), and wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is selected from lanaleximab, berositol, and C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®).
[0376] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, oral secifettostat (or its pharmaceutically acceptable saline and / or solvate) to a patient in need, wherein the HAE attack is an attack in the neck or above, and wherein the patient is given a first dose of about 300 mg of secifettostat (or its pharmaceutically acceptable saline and / or solvate), followed by a second dose of about 300 mg of secifettostat (or its pharmaceutically acceptable saline and / or solvate), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, and wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is selected from lanaleximab, berositol, and C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®).
[0377] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on demand, a first dose of approximately 300 mg of celefatestat (or its pharmaceutically acceptable saline and / or solvate) orally to a patient in need, wherein the HAE attack is an attack in the neck or above, and wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is selected from lanaleximab and berositol.
[0378] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, orally secfifeltstat (or its pharmaceutically acceptable saline and / or solvate) to a patient in need, wherein the HAE attack is an attack in the neck or above, and wherein the patient is given a first dose of about 300 mg of secfifeltstat (or its pharmaceutically acceptable saline and / or solvate), followed by a second dose of about 300 mg of secfifeltstat (or its pharmaceutically acceptable saline and / or solvate), and wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is selected from lanaleximab and berositstat.
[0379] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, secifetrestat (or its pharmaceutically acceptable saline and / or solvate) orally to a patient in need, wherein the HAE attack is an attack in the neck or above, and wherein a first dose of about 300 mg of secifetrestat (or its pharmaceutically acceptable saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of secifetrestat (or its pharmaceutically acceptable saline and / or solvate), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, and wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is selected from lanaleximab and berositol.
[0380] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, a first dose of approximately 300 mg of secfistat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the HAE attack is an attack in the neck or above, and wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is lanaleximab.
[0381] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, secfifestat (or its pharmaceutically acceptable saline and / or solvate) orally to a patient in need, wherein the HAE attack is an attack in the neck or above, and wherein the patient is given a first dose of about 300 mg of secfifestat (or its pharmaceutically acceptable saline and / or solvate), followed by a second dose of about 300 mg of secfifestat (or its pharmaceutically acceptable saline and / or solvate), and wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is lanaleximab.
[0382] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, orally secifexostat (or its pharmaceutically acceptable saline and / or solvate) to a patient in need, wherein the HAE attack is an attack in the neck or above, and wherein a first dose of about 300 mg of secifexostat (or its pharmaceutically acceptable saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of secifexostat (or its pharmaceutically acceptable saline and / or solvate), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, and wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is lanaleximab.
[0383] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on demand, a first dose of about 300 mg of secbetalstat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the HAE attack is an attack in the neck or above, and wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is berositol.
[0384] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, orally secifexostat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the HAE attack is an attack in the neck or above, and wherein the patient is given a first dose of about 300 mg of secifexostat (or its pharmaceutical saline and / or solvate), followed by a second dose of about 300 mg of secifexostat (or its pharmaceutical saline and / or solvate), and wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is berositol.
[0385] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, selenostat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the HAE attack is an attack in the neck or above, and wherein a first dose of about 300 mg of selenostat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of selenostat (or its pharmaceutical saline and / or solvate), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, and wherein the patient is also treated with a prophylactic agent for HAE, wherein the prophylactic agent is berositol.
[0386] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering, on demand, a first oral dose of approximately 300 mg of secbetasstat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the HAE episode is an episode in the neck or above, and wherein the patient is also treated with a prophylactic treatment agent for HAE, wherein the prophylactic treatment agent is a C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®).
[0387] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, oral selegiline (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the HAE attack is an attack in the neck or above, and wherein the patient is given a first dose of about 300 mg of selegiline (or its pharmaceutical saline and / or solvate), followed by a second dose of about 300 mg of selegiline (or its pharmaceutical saline and / or solvate), and wherein the patient is also treated with a prophylactic treatment for HAE, wherein the prophylactic treatment is a C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®).
[0388] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, oral selegiline statol (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the HAE attack is an attack in the neck or above, and wherein a first dose of about 300 mg of selegiline statol (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of selegiline statol (or its pharmaceutical saline and / or solvate), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, and wherein the patient is also treated with a prophylactic treatment for HAE, wherein the prophylactic treatment is a C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®).
[0389] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering, on demand, a first dose of approximately 300 mg of secbetalstat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the HAE episode is in the neck or above and wherein the patient has not been treated with a prophylactic agent for HAE.
[0390] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, orally secifexorstat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the HAE attack is an attack in the neck or above, and wherein a first dose of about 300 mg of secifexorstat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of secifexorstat (or its pharmaceutical saline and / or solvate), and wherein the patient has not yet been treated with a prophylactic agent for HAE.
[0391] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: on-demand oral administration of secfistat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the HAE attack is an attack in the neck or above, and wherein a first dose of about 300 mg of secfistat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of secfistat (or its pharmaceutical saline and / or solvate), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, and wherein the patient has not yet been treated with a prophylactic agent for HAE.
[0392] In any of the above embodiments, a HAE seizure is characterized as "mild" or worse according to the PGI-S scale. In one embodiment, a HAE seizure is characterized as "mild" according to the PGI-S scale. In another embodiment, a HAE seizure is characterized as "moderate" or worse according to the PGI-S scale. In one embodiment, a HAE seizure is characterized as "moderate" according to the PGI-S scale. Preferably, a HAE seizure is characterized as "severe" or worse according to the PGI-S scale. In particular, a HAE seizure is characterized as "severe" or "extremely severe" according to the PGI-S scale.
[0393] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering, on demand, a first dose of approximately 300 mg of celefatestat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the HAE episode is an episode occurring in the neck or above, and wherein the HAE episode is characterized as “severe” or above according to the PGI-S scale.
[0394] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering secfifestat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the HAE episode is an episode in the neck or above, and wherein a first dose of about 300 mg of secfifestat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of secfifestat (or its pharmaceutical saline and / or solvate), and wherein the HAE episode is characterized as “severe” or above according to the PGI-S scale.
[0395] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, seftiofur (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the HAE attack is an attack in the neck or above, and wherein a first dose of about 300 mg of seftiofur (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of seftiofur (or its pharmaceutical saline and / or solvate), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, and wherein the HAE attack is characterized as “severe” or worse according to the PGI-S scale.
[0396] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering, on demand, a first dose of approximately 300 mg of celefatestat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the HAE episode is an episode occurring in the neck or above, and wherein the HAE episode is characterized as “mild” or above according to the PGI-S scale.
[0397] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering, on-demand, secifetrestat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the HAE episode is an episode in the neck or above, and wherein a first dose of about 300 mg of secifetrestat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of secifetrestat (or its pharmaceutical saline and / or solvate), and wherein the HAE episode is characterized as “mild” or above according to the PGI-S scale.
[0398] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, celecoxib (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the HAE attack is an attack in the neck or above, and wherein a first dose of about 300 mg of celecoxib (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of celecoxib (or its pharmaceutical saline and / or solvate), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, and wherein the HAE attack is characterized as “mild” or worse according to the PGI-S scale.
[0399] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering, on demand, a first dose of approximately 300 mg of celefatestat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the HAE episode is an episode occurring in the neck or above, and wherein the HAE episode is characterized as “moderate” or above according to the PGI-S scale.
[0400] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering, on-demand, secifetrestat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the HAE episode is an episode in the neck or above, and wherein a first dose of about 300 mg of secifetrestat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of secifetrestat (or its pharmaceutical saline and / or solvate), and wherein the HAE episode is characterized as “moderate” or above according to the PGI-S scale.
[0401] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering celefatestat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the HAE attack is an attack in the neck or above, and wherein a first dose of about 300 mg of celefatestat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of celefatestat (or its pharmaceutical saline and / or solvate), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, and wherein the HAE attack is characterized as “moderate” or above according to the PGI-S scale.
[0402] Specific treatment for HAE attacks in the neck and above that do not originate in the laryngeal region.
[0403] Non-laryngotic attacks in the neck and above can rapidly progress to laryngeal attacks, which can be life-threatening. It is advantageous to treat such attacks to slow their progression to laryngeal attacks. It is advantageous to treat such attacks to reduce the severity of any resulting laryngeal attacks. It is advantageous to treat such attacks to prevent their progression or extension into laryngeal attacks. Where appropriate, any of the treatments described herein can therefore be used to treat non-laryngotic attacks in the neck and above. Specific implementation methods are shown below.
[0404] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on demand, a first dose of about 300 mg of celefatestat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the HAE attack is an attack in the neck or above, and wherein the attack in the neck or above is not an attack in the larynx.
[0405] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, secifetrestat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the HAE attack is an attack in the neck or above, and wherein a first dose of about 300 mg of secifetrestat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of secifetrestat (or its pharmaceutical saline and / or solvate), and wherein the neck or above attack is not a laryngeal attack.
[0406] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering celefatestat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the HAE attack is an attack in the neck or above, and wherein a first dose of about 300 mg of celefatestat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of celefatestat (or its pharmaceutical saline and / or solvate), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, and wherein the neck or above attack is not a laryngeal attack.
[0407] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, orally secifexorstat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the HAE attack is an attack in the neck or above, and wherein a first dose of about 300 mg of secifexorstat (or its pharmaceutical saline and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of secifexorstat (or its pharmaceutical saline and / or solvate), followed by a third dose of about 300 mg of secifexorstat (or its pharmaceutical saline and / or solvate), and wherein the neck or above attack is not a laryngeal attack.
[0408] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, orally to a patient in need of celefetrestat (or its pharmaceutical saline and / or solvate), wherein the HAE attack is an attack in the neck or above, and wherein the patient is given a first dose of about 300 mg of celefetrestat (or its pharmaceutical saline and / or solvate), followed by a second dose of about 300 mg of celefetrestat (or its pharmaceutical saline and / or solvate), followed by a third dose of about 300 mg of celefetrestat (or its pharmaceutical saline and / or solvate), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, wherein the third dose is administered about 2 to about 6 hours after the second dose, preferably about 3 hours after the second dose, and wherein the attack in the neck or above is not a laryngeal attack.
[0409] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: administering, on-demand, secifetrestat (or its pharmaceutical saline and / or solvate) orally to a patient in need, wherein the HAE attack is an attack in the neck or above, and wherein the patient is given a first dose of about 300 mg of secifetrestat (or its pharmaceutical saline and / or solvate), followed by a second dose of about 300 mg of secifetrestat (or its pharmaceutical saline and / or solvate), followed by a third dose of about 300 mg of secifetrestat (or its pharmaceutical saline and / or solvate), followed by a fourth dose of about 300 mg of secifetrestat (or its pharmaceutical saline and / or solvate), and wherein the neck or above attack is not a laryngeal attack.
[0410] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: on-demand oral administration of secfibetalistat (or its pharmaceutical saline and / or solvate) to a patient in need, wherein the HAE attack is an attack in the neck or above, and wherein the patient is given a first dose of about 300 mg of secfibetalistat (or its pharmaceutical saline and / or solvate), followed by a second dose of about 300 mg of secfibetalistat (or its pharmaceutical saline and / or solvate), followed by a third dose of about 300 mg of secfibetalistat (or its pharmaceutical saline and / or solvate), followed by a fourth dose of about 300 mg of secfibetalistat (or its pharmaceutical saline and / or solvate). mg of seletestat (or its pharmaceutical salt and / or solvate), wherein the second dose is administered about 2 to about 6 hours after the first dose, preferably about 3 hours after the first dose, wherein the third dose is administered about 2 to about 6 hours after the second dose, preferably about 3 hours after the second dose, and wherein the fourth dose is administered about 2 to about 6 hours after the third dose, preferably about 3 hours after the third dose, and wherein the onset in the neck and above is not a laryngeal onset.
[0411] In any of the above embodiments where the attack is in the neck or above and not in the throat, secbetalistat (or its pharmaceutical saline and / or solvate) slows the progression of the attack to a laryngeal attack. In another embodiment where the attack is in the neck or above and not in the throat, secbetalistat (or its pharmaceutical saline and / or solvate) reduces the severity of any resulting laryngeal attacks. In yet another embodiment where the attack is in the neck or above and not in the throat, the progression of the attack to a laryngeal attack is prevented.
[0412] Specific combination therapy
[0413] As mentioned above, the data documented in this article indicate that seviterus (a plasma kallikrein inhibitor) can be used on demand to treat HAE episodes in patients who are also being treated with prophylactic HAE agents (even when the prophylactic agent is also a plasma kallikrein inhibitor), particularly in cases where the HAE episodes are severe or very severe and / or where the HAE episodes are in the neck or above but not in the larynx. Neck and above episodes can be facial (i.e., facial seizures) and / or tongue seizures and / or pharyngeal seizures. Importantly, patients with a wide range of HAEs and a wide range of HAE episodes can benefit from on-demand treatment.
[0414] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering a plasma kallikrein inhibitor to a patient in need on demand, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the HAE episode is characterized as “severe” or above according to the PGI-S scale.
[0415] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering a plasma kallikrein inhibitor to a patient in need on demand, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the HAE episodes occur in the neck and above but not in the larynx.
[0416] Attacks in the neck and above can be facial and / or throat and / or tongue.
[0417] The above-described embodiments for treating severe or more serious HAE attacks, treating HAE attacks in patients receiving prophylactic medications, or medications, or any of the embodiments described below regarding drug-drug interactions, may be considered for combination with any of the embodiments described herein regarding specific combination therapies, where appropriate. Intended that any of these embodiments may be combined.
[0418] The specific combination therapies are shown below.
[0419] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering a plasma kallikrein inhibitor to a patient in need on demand, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the HAE episode is characterized as “severe” according to the PGI-S scale.
[0420] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering a plasma kallikrein inhibitor to a patient in need on demand, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the HAE episode is characterized as “extremely severe” according to the PGI-S scale.
[0421] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering a plasma kallikrein inhibitor to a patient in need on demand, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the HAE episode is characterized as “severe” or above according to the PGI-S scale, and wherein the HAE episode is selected from laryngeal episodes, neck and above episodes, abdominal episodes, and subcutaneous episodes.
[0422] HAE attacks can occur in the larynx. HAE attacks can occur in the neck and above. HAE attacks can occur in the abdomen. HAE attacks can occur subcutaneously. HAE attacks can occur in the neck and above but not in the larynx.
[0423] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) attacks, the method comprising: on-demand administration of a plasma kallikrein inhibitor to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the HAE attack is an attack in the neck or above but not in the larynx, and wherein the HAE attack is characterized as “mild” or worse according to the PGI-S scale. In one embodiment, the HAE attack is characterized as “mild” according to the PGI-S scale. In another embodiment, the HAE attack is characterized as “moderate” or worse according to the PGI-S scale. In one embodiment, the HAE attack is characterized as “moderate” according to the PGI-S scale. Preferably, the HAE attack is characterized as “severe” or worse according to the PGI-S scale. In particular, the HAE attack is characterized as “severe” or “very severe” according to the PGI-S scale.
[0424] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering a plasma kallikrein inhibitor to a patient in need on demand, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the HAE episode is an episode in the neck or above but not in the larynx, and wherein the HAE episode is characterized as “severe” or above according to the PGI-S scale.
[0425] In any of the above implementation schemes, the prophylactic treatment for HAE may be a PKa binder, a bradykinin B2 receptor antagonist, a factor XIIa (FXIIa) binder, or a C1INH substitute.
[0426] Prophylactic treatment for HAE can be a pKa binder, preferably a kallikrein inhibitor. Data in Example 4 demonstrate that secfistat (a kallikrein inhibitor) remains safe and effective in treating HAE episodes even when patients are already taking different kallikrein inhibitors as prophylactic treatments (specifically, lanaleximab or berositol). This is advantageous and confirms the availability and reliability of secfistat (a kallikrein inhibitor) in a wide range of relevant clinical situations, even when patients are taking prophylactic kallikrein inhibitors.
[0427] Prophylactic treatment for HAE can be bradykinin B2 receptor antagonists.
[0428] Prophylactic treatment for HAE can be factor XIIa (FXIIa) binders, preferably FXIIa inhibitors.
[0429] Prophylactic treatment for HAE can be a reduced-dose androgen. Specifically, a reduced-dose androgen can be danazol or oxandrolone. Prophylactic treatment for HAE can also be tranexamic acid. Alternatively, prophylactic treatment for HAE can be non-androgen therapy.
[0430] Prophylactic agents for HAE may be selected from lanazalimumab, dadaxisab, berositol, STAR 0215, C1INH replacement therapies (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®), donidalosin, and deucrictibant. In one embodiment, the prophylactic agent is selected from dadaxisab, STAR 0215, C1INH replacement therapies (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®), donidalosin, and deucrictibant.
[0431] Prophylactic treatment for HAE can be a C1 inhibitor. Specifically, prophylactic treatment can be Cinryze®, Haegarda®, or Berinert®.
[0432] Prophylactic treatments may include lanalidomide or berositol.
[0433] Prophylactic treatment may include lanalidomide.
[0434] Berosstat can be used as a preventative treatment.
[0435] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering a plasma kallikrein inhibitor to a patient in need on demand, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the HAE episode is characterized as “severe” or above according to the PGI-S scale, wherein the prophylactic agent is a factor XIIa (FXIIa) inhibitor.
[0436] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering a plasma kallikrein inhibitor to a patient in need on demand, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the HAE episodes occur in the neck and above but not in the larynx, wherein the prophylactic agent is a factor XIIa (FXIIa) inhibitor.
[0437] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering a plasma kallikrein inhibitor to a patient in need on demand, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the HAE episode is characterized as “severe” or above according to the PGI-S scale, wherein the prophylactic agent is a plasma kallikrein inhibitor.
[0438] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering a plasma kallikrein inhibitor to a patient in need on demand, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the HAE episodes occur in the neck and above but not in the larynx, wherein the prophylactic agent is a plasma kallikrein inhibitor.
[0439] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering a plasma kallikrein inhibitor to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the HAE episode is characterized as “severe” or above according to the PGI-S scale, wherein the prophylactic agent is selected from lanaleximab, dadaximab, berositol, STAR 0215, C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®), donidalosin, and deucrictibant.
[0440] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering a plasma kallikrein inhibitor to a patient in need on demand, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the HAE episodes occur in the neck and above but not in the larynx, wherein the prophylactic agent is selected from lanaleximab, dadaximab, berositol, STAR 0215, C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert® or Haegarda®), donidalosin, and deucrictibant.
[0441] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering a plasma kallikrein inhibitor to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the HAE episode is characterized as “severe” or above according to the PGI-S scale, wherein the prophylactic agent is selected from lanaleximab, berositol, and C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®).
[0442] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering a plasma kallikrein inhibitor to a patient in need on demand, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the HAE episodes occur in the neck and above but not in the larynx, wherein the prophylactic agent is selected from lanaleximab, berositol, and C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®).
[0443] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering a plasma kallikrein inhibitor to a patient in need on demand, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the HAE episode is characterized as “severe” or above according to the PGI-S scale, wherein the prophylactic agent is selected from lanaleximab and berositol.
[0444] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering a plasma kallikrein inhibitor to a patient in need on demand, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the HAE episodes occur in the neck and above but not in the larynx, wherein the prophylactic agent is selected from lanaleximab and berositol.
[0445] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering a plasma kallikrein inhibitor to a patient in need on demand, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the HAE episode is characterized as “severe” or above according to the PGI-S scale, wherein the prophylactic agent is lanaleximab.
[0446] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering a plasma kallikrein inhibitor to a patient in need on demand, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the HAE episodes occur in the neck and above but not in the larynx, wherein the prophylactic agent is lanaleximab.
[0447] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering a plasma kallikrein inhibitor to a patient in need on demand, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the HAE episode is characterized as “severe” or above according to the PGI-S scale, wherein the prophylactic agent is berosstat.
[0448] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering a plasma kallikrein inhibitor to a patient in need on demand, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the HAE episodes occur in the neck and above but not in the larynx, wherein the prophylactic agent is berosstat.
[0449] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering a plasma kallikrein inhibitor to a patient in need, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the HAE episode is characterized as “severe” or above according to the PGI-S scale, wherein the prophylactic agent is a C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®).
[0450] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering a plasma kallikrein inhibitor to a patient in need on demand, wherein the patient is also treated with a prophylactic agent for HAE, and wherein the HAE episodes occur in the neck and above but not in the larynx, wherein the prophylactic agent is a C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert®, or Haegarda®).
[0451] Drug-drug interactions
[0452] The data disclosed in this article confirm that drug-drug interactions can occur when secbetstatin (or its pharmaceutical salts and / or solvates) is administered co-administered with potent or moderate CYP3A4 inhibitors or CYP3A4 inducers. In particular, co-administration with potent or moderate CYP3A4 inhibitors or potent or moderate CYP3A4 inducers can affect the plasma concentrations of secbetstatin (or its pharmaceutical salts and / or solvates).
[0453] The co-administration of secbetstatin (or its pharmaceutically acceptable salts and / or solvates) with CYP3A4 inhibitors has the potential to increase or prolong the effects of secbetstatin (or its pharmaceutically acceptable salts and / or solvates). The co-administration of secbetstatin (or its pharmaceutically acceptable salts and / or solvates) with CYP3A4 inducers has the potential to decrease or reduce the effects of secbetstatin (or its pharmaceutically acceptable salts and / or solvates). These interactions may be expected to be considered with adequate dose adjustment.
[0454] Therefore, the present invention provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering secfibetalistat (or its pharmaceutical salt and / or solvate) orally to a patient in need, wherein the patient has taken or will take a combination dose of a potent or moderate CYP3A4 inhibitor and wherein the method comprises reducing the normal dose of secfibetalistat (or its pharmaceutical salt and / or solvate).
[0455] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: administering secbetalstat (or its pharmaceutically acceptable saline and / or solvate) orally to a patient in need, wherein the patient has taken or will take a combined dose of a potent or moderate CYP3A4 inducer and wherein the method comprises increasing the normal dose of secbetalstat (or its pharmaceutically acceptable saline and / or solvate).
[0456] For the avoidance of doubt, any of the above-described implementation schemes for treating severe or more serious HAE attacks, treating HAE attacks in patients receiving prophylactic treatment, medication, treating HAE attacks in the neck and above, or specific combination therapies may be considered in combination with any of the implementation schemes described herein regarding drug-drug interactions, where appropriate. It is intended that any of these implementation schemes may be combined.
[0457] Combination therapy can refer to the simultaneous, separate, or sequential administration of secbetstatin and a CYP3A4 inhibitor / inducer. For the avoidance of doubt, secbetstatin and the CYP3A4 inhibitor / inducer do not necessarily need to be administered at the same time; that is, secbetstatin and the CYP3A4 inhibitor / inducer can be administered at different times of the day.
[0458] As used in the context of this drug-drug interactions section, a “potent CYP3A4 inhibitor” is a drug that increases the AUC of a sensitive indicator substrate for a specified metabolic pathway by ≥ 5-fold. As used herein, a “moderate CYP3A4 inhibitor” is a drug that increases the AUC of a sensitive indicator substrate for a specified metabolic pathway by ≥ 2-fold to < 5-fold. As administered herein, a “potent CYP3A4 inducer” is a drug that reduces the AUC of a sensitive indicator substrate for a specified metabolic pathway by ≥ 80%. As used herein, a “moderate CYP3A4 inducer” is a drug that reduces the AUC of a sensitive indicator substrate for a specified metabolic pathway by ≥ 50% to < 80%. These definitions are consistent with the FDA definition (https: / / www.fda.gov / media / 134581 / download - see pages 23-24) and the EMA definition (https: / / www.ema.europa.eu / en / documents / scientific-guideline / guideline-investigation-drug-interactions-revision-1_en.pdf - see Appendix VIII).
[0459] Specific treatments considering potential drug-drug interactions
[0460] The present invention also provides a method for on-demand treatment of episodes of hereditary angioedema (HAE), the method comprising: on-demand oral administration of secfistat (or its pharmaceutically prepared saline and / or solvate) to a patient in need, wherein the patient has been taking or will take a combination dose of a potent or moderate CYP3A4 inhibitor, and wherein the method comprises reducing the normal dose of secfistat (or its pharmaceutically prepared saline and / or solvate) to mitigate the additive effect experienced when co-administered with a potent or moderate CYP3A4 inhibitor. In one embodiment, the additive effect is an increase in the therapeutic efficacy of secfistat (or its pharmaceutically prepared saline and / or solvate).
[0461] In any of the above embodiments, the dose of secbetstatin (or its pharmaceutical saline and / or solvate) is reduced by about 10% to about 60% compared to the patient's normal dose. The dose of secbetstatin (or its pharmaceutical saline and / or solvate) is reduced by about 20% to about 50% compared to the patient's normal dose. The dose of secbetstatin (or its pharmaceutical saline and / or solvate) is reduced by about 30% to about 50% compared to the patient's normal dose. The dose of secbetstatin (or its pharmaceutical saline and / or solvate) is reduced by about 40% to about 50% compared to the patient's normal dose. Specifically, the dose of secbetstatin (or its pharmaceutical saline and / or solvate) is reduced by about 50% compared to the patient's normal dose.
[0462] In any of the above implementation schemes, the patient's "normal dose" is preferably 300 mg.
[0463] In some implementations, the CYP3A4 inhibitor is a potent CYP3A4 inhibitor. A potent CYP3A4 inhibitor may be selected from itraconazole, ketoconazole, ritonavir, elvitegravir combined with ritonavir, indinavir combined with ritonavir, lopinavir combined with ritonavir, clarithromycin, ceritinib, cobicistat, and idelalis. IB), nefazodone, nelfinavir, paritaprevir with ritonavir with (ombitasvir and / or dasabuvir), posaconazole, saquinavir with ritonavir, telithromycin, tipranavir with ritonavir, voriconazole Darunavir, telaprevir, stiripentol, curcumin, troleandomycin, atazanavir, naloxone, nilotinib, delavirdine, loperamide, ribociclib, danoprevir, midostaurin, terfenadine, ergotamine, econazole, ditiocarb, methimazole, boceprevir, lonafarnib, amprenavir, amiodarone, and levoketoconazole.
[0464] In other implementations, the CYP3A4 inhibitor is a moderate CYP3A4 inhibitor. A moderate CYP3A4 inhibitor may be selected from verapamil, aprepitant, ciprofloxacin, conivaptan, crizotinib, diltiazem, dronedarone, erythromycin, fluconazole, and grapefruit juice. juice), imatinib, isavuconazole, isavuconazonium, luliconazole, netupitant, miconazole, nicardipine, isoniazid, danazol, lovastatin, ziprasidone, desvenlafaxine, indalpine, zimelidine, milnacipran, fusidic acid The following are listed: acid, barnidipine, benidipine, isradipine, haloperidol, linagliptin, fosnetupitant, simeprevir, nilvadipine, primaquine, clozapine, tioconazole, venetoclax, seproxetine, fluvoxamine, fosamprenavir, cyclosporine, abiraterone, clindamycin, berootralstat, tepotinib, and lenacapavir.
[0465] The present invention also provides a method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: on-demand oral administration of secfistat (or its pharmaceutically prepared saline and / or solvate) to a patient in need, wherein the patient has taken or will take a combined dose of a potent or moderate CYP3A4 inducer, and wherein the method comprises increasing the normal dose of secfistat (or its pharmaceutically prepared saline and / or solvate) to compensate for effects experienced during co-administration. In one embodiment, the effect experienced during co-administration is a reduction in the therapeutic efficacy of secfistat (or its pharmaceutically prepared saline and / or solvate).
[0466] In any of the above embodiments, the dose of secbetstatin (or its pharmaceutical saline and / or solvate) is increased by about 10% to about 60% compared to the patient's normal dose. The dose of secbetstatin (or its pharmaceutical saline and / or solvate) is increased by about 20% to about 50% compared to the patient's normal dose. The dose of secbetstatin (or its pharmaceutical saline and / or solvate) is increased by about 30% to about 50% compared to the patient's normal dose. The dose of secbetstatin (or its pharmaceutical saline and / or solvate) is increased by about 40% to about 50% compared to the patient's normal dose. Specifically, the dose of secbetstatin (or its pharmaceutical saline and / or solvate) is increased by about 50% compared to the patient's normal dose.
[0467] In any of the above implementation schemes, the patient's "normal dose" is preferably 300 mg.
[0468] In some implementations, the CYP3A4 inducer is a potent CYP3A4 inducer. Potent CYP3A4 inducers can be selected from 3-phenytoin, fosphenytoin, apalutamide, carbamazepine, enzalutamide, ivosidenib, lumacaftor and ivacaftor, mitotane, rifampin, St. John's wort, pentobarbital, phenobarbital, enzalutamide, rimexolone, rifaximin, rifamycin, midostaurin, dexamethasone, and rifapentine.
[0469] In other embodiments, the CYP3A4 inducer is a moderate CYP3A4 inducer. A moderate CYP3A4 inducer may be selected from efavirenz, bosentan, cenobamate, dabrafenib, etravirine, lorlatinib, pexidartinib, phenobarbital, primidone, sotorasib, modafinil, nafcillin, bexarotene, avasimibe, echinacea, dexamethasone, and dexamethasone acetate.
[0470] Other implementation schemes applicable to any of the treatments described herein
[0471] In any treatment of the invention described herein, selegiline statrol is administered orally in a therapeutically effective dose. Unless otherwise stated, a therapeutically effective dose may be about 100 mg to about 1500 mg, about 300 mg to about 1800 mg, about 100 mg to about 1400 mg, about 200 mg to about 1200 mg, about 300 mg to about 1200 mg, about 600 mg to about 1200 mg, about 450 mg to about 900 mg, about 500 mg to about 1000 mg, about 450 mg to about 600 mg, about 500 mg to about 700 mg (more specifically 600 mg), about 800 mg to about 1000 mg (daily), about 900 mg to about 1400 mg (more specifically 1200 mg), or about 900 mg to about 1200 mg. The therapeutically effective dose may be about 250 mg to about 350 mg, about 270 mg to about 330 mg, about 275 mg to about 325 mg, about 285 mg to about 315 mg, about 290 mg to about 310 mg, or about 295 mg to about 305 mg. Preferably, the therapeutically effective dose is about 300 mg. As used herein, "about" means ± 10%.
[0472] In any of the embodiments described herein, seletestat is preferably in the form of a free base.
[0473] In any of the embodiments described herein, the patient may be 12 years of age or older. Specifically, the patient may be 12 years of age or older but under 18 years of age. Alternatively, the patient may be 18 years of age or older.
[0474] In any of the embodiments described herein, secbetalstat (or its pharmaceutical salts and / or solvates) is administered to reduce the time required for symptom relief to begin. In this context, the term "symptom relief" may mean that, when assessed according to the PGI-C scale, the seizure was rated "slightly better" or better at two consecutive time points. The PGI-C is an indicator known in the art that can be used to score the progression of HAE seizures and report seizures as "significantly better," "better," "slightly better," "no change," "slightly worse," "worse," or "significantly worse."
[0475] When assessed using the PGI-C scale, in any treatment of the present invention, secbetalstat is administered to reduce the time required for the onset of symptom relief to approximately 0.7 hours to approximately 8 hours after the first dose of secbetalstat. Symptom relief may begin approximately 1 hour to approximately 8 hours after the first dose. Symptom relief may begin approximately 1 hour to approximately 6 hours after the first dose of secbetalstat. Symptom relief may begin approximately 1 hour to approximately 4 hours after the first dose of secbetalstat. Symptom relief may begin approximately 1 hour to approximately 2 hours after the first dose. Symptom relief may begin approximately 1.5 hours to approximately 1.8 hours after the first dose. Symptom relief may begin approximately 1.61 hours after the first dose of secbetalstat.
[0476] In any of the implementation schemes described herein, secbetalstat (or its pharmaceutical saline and / or solvate) is administered to reduce the time required to achieve seizure severity reduction. In this context, the term "seizure severity reduction" can refer to a decrease in seizure severity of one or more grades from baseline on the PGI-S scale at two consecutive time points.
[0477] When assessed using the PGI-S scale, in any treatment of the present invention, secbetalstat is administered to reduce the time required for reduction of seizure severity to approximately 1 hour to approximately 12 hours. Reduction of seizure severity may begin in approximately 2 hours to approximately 11 hours. Reduction of seizure severity may begin in approximately 3 hours to approximately 10 hours. Reduction of seizure severity may begin in approximately 5 hours to approximately 10 hours. Reduction of seizure severity may begin in approximately 9 hours to approximately 10 hours. Reduction of seizure severity may begin in approximately 9 hours to approximately 9.5 hours. Reduction of seizure severity may begin in approximately 9.27 hours.
[0478] In any of the implementation schemes described herein, secbetalstat (or its pharmaceutical saline and / or solvate) is administered to achieve complete seizure resolution. In this context, the term "complete seizure resolution" can mean that, when assessed using the PGI-S scale, treatment improves seizure severity to "none".
[0479] When assessed using the PGI-S scale, in any treatment of the present invention, secbetalstat is administered to achieve complete seizure resolution within approximately 8 hours to approximately 24 hours. Complete seizure resolution may be achieved within 24 hours. Complete seizure resolution may be achieved within approximately 8 hours to approximately 20 hours. Complete seizure resolution may be achieved within approximately 8 hours to approximately 17 hours. Complete seizure resolution may be achieved within approximately 8 hours to approximately 13 hours. Complete seizure resolution may be achieved within approximately 8 hours to approximately 10 hours.
[0480] Dosage forms that can be used for the treatments described in this article
[0481] In any of the embodiments described herein, secbetalstat (or its pharmaceutical salts and / or solvates) may preferably be administered as part of the pharmaceutical composition. secbetalstat (or its pharmaceutical salts and / or solvates) may be administered as an oral dosage form comprising: (i) secbetalstat (or its pharmaceutical salts and / or solvates), and (ii) at least one pharmaceutical excipient. The oral dosage form may be a capsule. The oral dosage form may be a tablet. In particular, the tablet may be a film-coated tablet or an orally disintegrating tablet.
[0482] The oral dosage form may be a film-coated tablet containing microcrystalline cellulose as a diluent, croscarmellose sodium as a disintegrant, polyvinylpyrrolidone as a binder, and optionally magnesium stearate as a lubricant. In a preferred tablet, cerbutaline comprises: (i) at least about 40% by weight of tablets (more specifically, about 40% to about 60% by weight) (relative to the total weight of tablets); (ii) about 25% to about 60% by weight of a diluent (more specifically, about 25% to about 40% by weight) (relative to the total weight of tablets); (iii) about 1% to about 15% by weight of a disintegrant (more specifically, about 2% to about 6% by weight) (relative to the total weight of tablets); (iv) about 1% to about 20% by weight of a binder (more specifically, about 2% to about 5% by weight) (relative to the total weight of tablets); and, when present, (v) about 0.1% to about 5% by weight of a lubricant (more specifically, about 0.1% to about 1.5% by weight) (relative to the total weight of tablets). The dosage form may be a tablet containing about 250 mg to about 350 mg of cerbutaline (or its pharmaceutical salts and / or solvates). The dosage form may be a tablet containing about 270 mg to about 330 mg of clemetstat (or its pharmaceutically acceptable salts and / or solvates). The dosage form may be a tablet containing about 275 mg to about 325 mg of clemetstat (or its pharmaceutically acceptable salts and / or solvates). The dosage form may be a tablet containing about 285 mg to about 315 mg of clemetstat (or its pharmaceutically acceptable salts and / or solvates). The dosage form may be a tablet containing about 290 mg to about 310 mg of clemetstat (or its pharmaceutically acceptable salts and / or solvates). The dosage form may be a tablet containing about 295 mg to about 305 mg of clemetstat (or its pharmaceutically acceptable salts and / or solvates). Preferably, the dosage form may be a tablet containing about 300 mg of clemetstat (or its pharmaceutically acceptable salts and / or solvates).
[0483] The tablets may also contain excipients for external use, including: microcrystalline cellulose as an external diluent, sodium croscarmellose as an external disintegrant, polyvinylpyrrolidone as an external binder, and / or magnesium stearate as an external lubricant.
[0484] The dosage forms (e.g., tablets) described herein can be film-coated, wherein the film coating may contain one or more of hydroxypropyl methylcellulose, lactose monohydrate, titanium dioxide, and triacetin.
[0485] In any of the embodiments described herein, seviterus is administered as an orally disintegrating tablet. The orally disintegrating tablet may contain one or more of mannitol as a filler (e.g., granulated mannitol and / or spray-dried mannitol (e.g., Mannogem EZ®)), microcrystalline cellulose as a binder (e.g., silanized microcrystalline cellulose), and polyvinylpyrrolidone (crosspovidone) as a disintegrant. Specifically, the orally disintegrating tablet may contain about 25% to about 50% by weight of seviterus (or its pharmaceutical salts and / or solvates), one or more fillers (e.g., granulated mannitol and / or spray-dried mannitol) present in about 30% to 80% by weight of the orally disintegrating tablet, one or more binders (e.g., silanized microcrystalline cellulose) present in about 5% to about 30% by weight of the orally disintegrating tablet, and one or more disintegrants (e.g., polyvinylpyrrolidone (crosspovidone)) present in about 1% to about 10% by weight of the orally disintegrating tablet.
[0486] symptom
[0487] In the treatment of this invention, secfibetalistat (or its pharmaceutical saline and / or solvate) can be administered orally as needed after the symptoms of a HAE attack are identified. In the treatment of this invention, secfibetalistat (or its pharmaceutical saline and / or solvate) can be administered orally as needed at the earliest identification of a HAE attack. In the treatment of this invention, secfibetalistat (or its pharmaceutical saline and / or solvate) can be administered orally as needed for the treatment of a patient-identified HAE attack.
[0488] Although each HAE episode may vary in severity and affected area, patients experiencing HAE, healthcare professionals knowledgeable about HAE, and caregivers (and indeed technicians) of HAE patients will be able to readily identify the symptoms of an HAE episode. These symptoms include, but are not limited to: swelling of tissues in the hands, feet, extremities, face, intestines, and / or airways; fatigue; headache; muscle aches; skin tingling; abdominal pain; nausea; vomiting; diarrhea; dysphagia; hoarseness; shortness of breath; and / or mood changes. Therefore, in some implementations, secbetalstat (or its pharmaceutical saline and / or solvates) may be administered after at least one of the above symptoms has been identified.
[0489] Technicians will also understand that "administer after the symptoms of a HAE attack are recognized" means administering the medication as soon as feasible after the symptoms of a HAE attack are recognized. For example, it is anticipated that the patient will have convenient and quick access to secbetalstat (or its pharmaceutical saline and / or solvates) (most likely in the form of a pharmaceutical composition) to ensure that treatment can be initiated after the symptoms of a HAE attack are recognized. In other words, treatment is administered on demand. For example, secbetalstat can be administered within 1 hour of the recognition of symptoms of a HAE attack, preferably within approximately 50 minutes, 40 minutes, 30 minutes, 20 minutes, 10 minutes, 6 minutes, or 5 minutes after the recognition of symptoms of an acute HAE attack.
[0490] If the symptoms of a HAE attack are recognized during the prodromal phase, secbeceptistat (or its pharmaceutical saline and / or solvates) can be administered during the prodromal phase. In these cases, the recognized symptom may be mild swelling, particularly mild swelling affecting the face and neck. Alternatively, the symptom may be abdominal pain, which is particularly considered characteristic of HAE attacks. Alternatively, the symptom may be skin redness, such as erythema marginalis.
[0491] In any of the above treatments, the symptoms can be recognized by the patient. In any of the above treatments, the symptoms can be recognized by a healthcare professional (such as a healthcare professional with HAE knowledge). In any of the above treatments, the symptoms can be recognized by the patient's caregiver.
[0492] Attached Figure
[0493] In the accompanying drawings, the term "compound" refers to seletestatin.
[0494] Figure 1 X-ray powder diffraction pattern of sèbetestrogen produced in Example 1.
[0495] Figure 2 The graph shows the distribution of epileptic seizure severity (PGI-S) at baseline in patients using on-demand treatment ± LTP.
[0496] Figure 3 The graph shows the distribution of attack severity (PGI-S) at baseline in patients using secbetstatin 300 mg, secbetstatin 600 mg, or placebo.
[0497] Figure 4 The graph shows the time from the onset of an attack to the first IMP administration.
[0498] Figure 5 The chart shows the cumulative percentage of patients with symptom relief (PGI-C) within 12 hours after IMP administration.
[0499] Figure 6 The chart shows the cumulative percentage of patients with reduced seizure severity (PGI-S) within 12 hours after IMP administration.
[0500] Figure 7 The chart shows the cumulative percentage of patients who achieved complete episodic resolution (PGI-S) within 24 hours of IMP administration.
[0501] Figure 8 The graph shows the cumulative percentage of patients with a 50% reduction in the composite VAS score within 24 hours after IMP administration.
[0502] Figure 9 The graph shows the plasma concentrations of selenostatin when administered alone and when used in combination with the potent CYP3A4 inhibitor itraconazole.
[0503] Figure 10 The graph shows the plasma concentrations of selenostatin when administered alone and when used in combination with the potent CYP3A4 inhibitor itraconazole.
[0504] Figure 11 The graph shows the plasma concentrations of selenostatin when administered alone and when administered with the potent CYP3A4 inducer phenytoin.
[0505] Figure 12 The graph shows the plasma concentrations of selenostatin when administered alone and when administered with the potent CYP3A4 inducer phenytoin.
[0506] Figure 13 The graph shows the plasma concentrations of selenostatin when administered alone and when combined with the moderate CYP3A4 inhibitor verapamil.
[0507] Figure 14 The graph shows the plasma concentrations of selenostatin when administered alone and when combined with the moderate CYP3A4 inhibitor verapamil.
[0508] Figure 15 The graph shows the plasma concentrations of selenostatin when administered alone and when administered with the moderate CYP3A4 inducer efavirenz.
[0509] Figure 16 The graph shows the plasma concentrations of selenostatin when administered alone and when administered with the moderate CYP3A4 inducer efavirenz.
[0510] Figure 17 The chart shows the proportion of attacks that reached the primary or key secondary endpoint with one or two doses of seletestat.
[0511] Figure 18 The graph shows the hazard ratios of 600 mg selebutatin versus 300 mg for primary or key secondary endpoints based on baseline attack severity.
[0512] Figure 19 The graph shows the hazard ratio of 600 mg selebutatine versus 300 mg for primary or key secondary endpoints in each treatment modality.
[0513] Figure 20 The graph shows the number of seizures treated with serbetuxat in the open-label extended phase 3 study (Example 5).
[0514] Figure 21 The graph shows the time from seizure identification to serbetuxat administration in the open-label extended phase 3 study of serbetuxat (Example 5).
[0515] Figure 22 The graph shows the time from the onset of an attack to the application of treatment (Example 4).
[0516] Figure 23 A graph showing the probability of faster complete seizure resolution (Example 4) is displayed.
[0517] Figure 24 The graph shows the time it takes for "mild" or "moderate" or higher seizures to completely resolve within 24 hours relative to the time of treatment for "earlier" and "later" treatments (Example 4).
[0518] Figure 25 : A LOESS regression curve was fitted to the time required to achieve complete resolution of the attack within 24 hours relative to the time of treatment (Example 4).
[0519] Figure 26 The graphs showing the baseline severity of attacks involving the larynx are illustrated (Examples 4 and 5).
[0520] Figure 27 The graph shows the time to treatment application for all episodes treated in Example 4, all episodes treated in Example 5, and episodes involving the larynx treated in Examples 4 and 5.
[0521] Figure 28 The graphs show the proportion of larynx-related episodes that reached the primary and key secondary endpoints without additional doses (Examples 4 and 5).
[0522] Figure 29 The graph shows the efficacy of serbetosterol in participants receiving LTP during the open-label extended phase 3 study of serbetosterol (Example 5).
[0523] Figure 30 The graph shows the efficacy of serbetosterol in participants receiving berostosterol during the open-label extended phase 3 study of serbetosterol (Example 5).
[0524] Figure 31 The graph shows the efficacy endpoints of serbetstatin in treating laryngeal episodes during the open-label extended phase 3 study (Example 5).
[0525] The embodiments provided herein can be more fully understood by referring to the following examples. These examples are intended to illustrate the treatments provided herein, but are not intended to limit the scope of the invention in any way. In fact, the scope of the invention is defined by the claims.
[0526] While examples of certain particular embodiments are provided herein, it will be apparent to those skilled in the art that various changes and modifications can be made. Such changes are also intended to fall within the scope of the appended claims.
[0527] General experimental details
[0528] In the following embodiments, the following abbreviations and definitions are used:
[0529]
[0530] Unless otherwise stated, all reactions were carried out under a nitrogen atmosphere.
[0531] 1 The H NMR spectra were recorded with reference to deuterium solvent and at room temperature on a Bruker (400MHz) or JEOL (400MHz) spectrometer.
[0532] Molecular ions were obtained using LC-MS with a Chromolith Speedrod RP-18e column (50 × 4.6 mm) and a linear gradient of 10% to 90% 0.1% HCO₂H / MeCN to 0.1% HCO₂H / H₂O over 13 min at a flow rate of 1.5 mL / min; or using Agilent X-Select (acidic) with 5-95% MeCN / water over 4 min. Data were acquired using a Thermofinnigan SurveyorMSQ mass spectrometer with electrospray ionization in conjunction with a Thermofinnigan Surveyor LC system.
[0533] Alternatively, molecular ions were obtained using LCMS with an Agilent Poroshell 120 EC-C18 (2.7 μm, 3.0 × 50 mm) column, employing 0.1% v / v formic acid aqueous solution [eluent A]; MeCN [eluent B]; a flow rate of 0.8 mL / min and an inter-sample equilibration time of 1.5 min, as shown below. Mass assays were performed using an API 2000 mass spectrometer (electrospray ionization).
[0534] gradient:
[0535]
[0536] In cases where the product is purified by rapid chromatography, "silica" refers to silica gel used for chromatography, 0.035 to 0.070 mm (220 to 440 mesh) (e.g., Merck silica gel 60), and column elution is accelerated by applying nitrogen pressure up to 10 psi. Reversed-phase preparative HPLC purification is performed using a Waters 2996 photodiode array detector at a flow rate typically 20 mL / min using a Waters 2525 binary gradient pump system.
[0537] All solvents and commercial reagents were used as is.
[0538] The chemical names are generated using automated software, such as Autonom software, which is provided as part of the ISIS Draw package from MDL Information Systems, or Chemaxon software, which is provided as a component of MarvinSketch or as a component of IDBSE-WorkBook.
[0539] Unless otherwise stated, X-ray powder diffraction patterns were acquired on a Philips X-Pert MPD diffractometer and analyzed using the following experimental conditions (Method A):
[0540] Tube anode: Cu
[0541] Generator voltage: 40 kV
[0542] Tube current: 40 mA
[0543] α1 wavelength: 1.5406 Å
[0544] α2 wavelength: 1.5444 Å
[0545] Starting angle [2θ]: 4
[0546] Termination angle [2θ]: 40
[0547] Continuous scanning
[0548] Approximately 2 mg of the sample to be analyzed was gently pressed onto an XRPD zero-background mono-oblique silica sample holder. The sample was then loaded into the diffractometer for analysis.
[0549] Example 1 - Preparation of selenostatin
[0550] A. 1-(4-hydroxymethyl-benzyl)-1H-pyridin-2-one
[0551] 4-(chloromethyl)benzyl alcohol (5.0 g, 31.93 mmol) was dissolved in acetone (150 mL). 2-hydroxypyridine (3.64 g, 38.3 mmol) and potassium carbonate (13.24 g, 95.78 mmol) were added, and the reaction mixture was stirred at 50 °C for 3 hours. The solvent was then removed under vacuum, and the residue was placed in chloroform (100 mL). The solution was washed with water (30 mL) and brine (30 mL), dried (Na₂SO₄), and evaporated under vacuum. The residue was purified by rapid chromatography (silica) with 3% MeOH / 97% CHCl₃ as eluent to give a white solid, identified as 1-(4-hydroxymethyl-benzyl)-1H-pyridin-2-one (5.30 g, 24.62 mmol, 77% yield).
[0552] [M+Na] + = 238
[0553] B. 1-(4-chloromethyl-benzyl)-1H-pyridin-2-one
[0554] 1-(4-hydroxymethyl-benzyl)-1H-pyridin-2-one (8.45 g, 39.3 mmol), anhydrous DCM (80 mL), and triethylamine (7.66 mL, 55.0 mmol) were cooled in an ice bath. Methanesulfonyl chloride (3.95 mL, 51.0 mmol) was added, and the mixture was stirred in an ice bath for 15 minutes. The ice bath was removed, and stirring continued overnight at room temperature. The reaction mixture was partitioned between DCM (100 mL) and a saturated aqueous solution of NH4Cl (100 mL). The aqueous layer was extracted with a further amount of DCM (2 × 50 mL), and the combined organic layers were washed with brine (50 mL), dried over Na2SO4, filtered, and concentrated to give 1-(4-chloromethyl-benzyl)-1H-pyridin-2-one (8.65 g, 36.6 mmol, 93% yield) as a pale yellow solid.
[0555] [MH] + = 234.1
[0556] C. Methyl 3-(methoxymethyl)-1-(4-((2-oxopyridin-1(2H)-yl)methyl)benzyl)-1H-pyrazole-4-carboxylic acid
[0557] Potassium carbonate (519 mg, 3.76 mmol) was added to a solution of methyl 3-(methoxymethyl)-1H-pyrazole-4-carboxylate (320 mg, 1.88 mmol; CAS No. 318496-66-1 (synthesized according to the method described in WO 2012 / 009009)) and 1-(4-(chloromethyl)benzyl)pyridin-2(1H)-one (527 mg, 2.26 mmol) in DMF (5 mL), and heated overnight at 60 °C. The reaction mixture was diluted with EtOAc (50 mL) and washed with brine (2 × 100 mL), dried over magnesium sulfate, filtered, and reduced under vacuum. The crude product was purified by rapid chromatography (40 g column, 0-100% EtOAc, in isohexane) to give two regiomeric isomers. The second isomer was collected from the column to give methyl 3-(methoxymethyl)-1-(4-((2-oxopyridin-1(2H)-yl)methyl)benzyl)-1H-pyrazole-4-carboxylate (378 mg, 1.01 mmol, 53.7% yield), as a colorless gel.
[0558] [MH] + = 368.2
[0559] D. 3-(methoxymethyl)-1-(4-((2-oxopyridin-1(2H)-yl)methyl)benzyl)-1H-pyrazole-4-carboxylic acid
[0560] Methyl 3-(methoxymethyl)-1-(4-(((2-oxopyridin-1(2H)-yl)methyl)benzyl)-1H-pyrazole-4-carboxylic acid (3.77 g, 10.26 mmol) was added to 2M NaOH solution (15.39 mL, 30.8 mmol) in THF (5 mL) and MeOH (5 mL) and stirred overnight at room temperature. 1M HCl (50 mL) was added and the mixture was extracted with EtOAc (50 mL). The organic layer was washed with brine (50 mL), dried over magnesium sulfate, filtered, and concentrated under vacuum to give 3-(methoxymethyl)-1-(4-((2-oxopyridin-1(2H)-yl)methyl)benzyl)-1H-pyrazole-4-carboxylic acid (1.22 g, 3.45 mmol, 33.6% yield) as a white powder.
[0561] [MH] + = 354.2
[0562] E. 3-Fluoro-4-methoxy-pyridine-2-carboxynitrile
[0563] Cuprous cyanide (I) (1.304 g, 14.56 mmol) was added to a solution of 2-bromo-3-fluoro-4-methoxypyridine (1 g, 4.85 mmol) in DMF (5 mL) in a large microwave-safe flask. The flask was sealed and heated to 100 °C for 16 hours. The reaction mixture was diluted with water (20 mL) and EtOAc (20 mL). The thick suspension was sonicated, and additional water (40 mL) and EtOAc (2 × 50 mL) were added during sonication to break up the precipitated solids. The combined layers were filtered through a diatomaceous earth mat, and the organic layer was separated, washed with brine (50 mL), dried over magnesium sulfate, filtered, and the solution was removed under reduced pressure to give a pale green solid, which was identified as the desired compound 3-fluoro-4-methoxy-pyridine-2-carboxynitrile (100 mg, 0.578 mmol, 12% yield).
[0564] F. (3-Fluoro-4-methoxy-pyridin-2-ylmethyl)-tert-butyl carbamate
[0565] 3-Fluoro-4-methoxy-pyridine-2-carboxynitrile (100 mg, 0.578 mmol) was dissolved in anhydrous methanol (10 mL, 247 mmol), and nickel chloride hexahydrate (14 mg, 0.058 mmol) was added, followed by di-tert-butyl dicarbonate (255 mg, 1.157 mmol). The resulting pale green solution was cooled to -5 °C in an ice-salt bath, and sodium borohydride (153 mg, 4.05 mmol) was added in portions while maintaining the reaction temperature at ~0 °C. The dark brown solution was stirred at 0 °C and slowly warmed to room temperature, then stirred at room temperature for 3 hours. The reaction mixture was evaporated to dryness at 40 °C to give a black residue, which was diluted with DCM (10 mL) and washed with sodium bicarbonate (10 mL). Due to the formation of an emulsion, the organic phase was separated and concentrated via a phase separator. The crude liquid was purified by chromatography using EtOAc / isohexane elution to give the title compound (3-fluoro-4-methoxy-pyridin-2-ylmethyl)-tert-butyl carbamate as a clear yellow oil (108 mg, 62% yield).
[0566] [MH] + = 257
[0567] G. C-(3-fluoro-4-methoxy-pyridin-2-yl)-methylamine hydrochloride
[0568] (3-fluoro-4-methoxy-pyridin-2-ylmethyl)-tert-butyl carbamate (108 mg, 0.358 mmol) was added to isopropanol (1 mL), followed by the addition of HCl (6N, in isopropanol) (1 mL, 0.578 mmol) at room temperature, and stirring at 40 °C for 2 hours. The reaction mixture was concentrated under reduced pressure, then ground with diethyl ether, sonicated, and decanted to give a milky white solid (75 mg, 55% yield), which was identified as C-(3-fluoro-4-methoxy-pyridin-2-yl)-methylamine hydrochloride.
[0569] [MH] + = 157
[0570] Example 1a - N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2- Oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide (Sebatestat)
[0571] 3-(methoxymethyl)-1-(4-(((2-oxopyridin-1(2H)-yl)methyl)benzyl)-1H-pyrazole-4-carboxylic acid (825 mg, 2.34 mmol) and C-(3-fluoro-4-methoxy-pyridin-2-yl)-methylamine hydrochloride (450 mg, 2.34 mmol) were dissolved in DCM and cooled to 0°C. 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (627.0 mg, 3.27 mmol), HOBt (378.8 mg, 2.80 mmol), and triethylamine (1.63 mL, 1182 mmol) were added, and the mixture was stirred until it reached room temperature and stirred for 20 hours. Chloroform (50 mL) was added, and the mixture was washed with saturated NaHCO3(aq) and concentrated under vacuum. The crude product was purified by chromatography using methanol / DCM elution. The solvent was removed under vacuum, and the resulting solid was ground with diethyl ether. The resulting solid was collected by filtration to obtain selenostatin.
[0572] [MH] + = 492.0
[0573] NMR (CD3OD) δ: 3.41 (3H, s), 4.03 (3H, s), 4.65 (2H, s), 4.72 (2H, d,J=2.3Hz), 5.24 (2H, s), 5.37 (2H, s), 6.44 (1H, td, J = 1.4, 6.8Hz), 6.62(1H, d, J = 9.0Hz), 7.18-7.22 (1H, m), 7.31-7.38 (4H, m), 7.56-7.60 (1H, m),7.75 (1H, dd, J = 1.9, 7.1Hz), 8.18 (1H, s), 8.27 (1H, d, J = 5.6Hz) ppm.
[0574] The XRPD diffraction pattern of semaphore obtained from the above procedure is shown in the figure. Figure 1 middle.
[0575] Peak position table:
[0576]
[0577] Example 2 - Preparation of a dosage form containing ceftazidime
[0578] Blending and rolling
[0579] Equipment: Freund Vector TFC laboratory miniature roller press and granulator (the roller press and granulator are separate entities). Equipment parameters are shown below:
[0580]
[0581] method
[0582] Three tablet formulations (tablets A, B, and C) were prepared on a 30g blending scale according to the following method to produce tablets having the amounts of components shown below.
[0583]
[0584] For each tablet, the blend was prepared as follows: using a Turbula blender (34 rpm), in a glass container, the granular components were pa...
Claims
1. A method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: Serbexeter (or its pharmaceutical saline and / or solvate) is administered orally to patients in need as required, wherein the HAE episode is characterized as “severe” or above according to the PGI-S scale.
2. The method of claim 1, wherein a first dose of about 300 mg of secbetstatin (or its pharmaceutical salt and / or solvate) is administered to the patient.
3. The method of claim 2, wherein a second dose of about 300 mg of secbetstatin (or its pharmaceutical salt and / or solvate) is administered to the patient.
4. The method according to any one of claims 1 to 3, wherein the patient is also treated with a prophylactic agent of HAE.
5. A method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: As needed, administer orally the first dose of approximately 300 mg of seviratestastat (or its pharmaceutical saline and / or solvate) to patients who are also being treated with prophylactic agents of HAE.
6. The method according to claim 5, wherein the prophylactic therapeutic agent is selected from pKa binders, bradykinin B2 receptor antagonists, factor XIIa (FXIIa) binders, or ClINH substitutes.
7. The method of claim 5, wherein the preventive therapeutic agent is a factor XIIa (FXIIa) inhibitor.
8. The method of claim 5, wherein the preventive therapeutic agent is a plasma kallikrein inhibitor.
9. The method of claim 5, wherein the prophylactic agent is selected from lanaleximab, dadaximab, berositol, STAR 0215, C1INH replacement therapy (such as Cinryze®, Ruconest®, Berinert® or Haegarda®), donidalosin, and deucrictibant.
10. The method according to claims 5 to 9, wherein the patient is given a second dose of about 300 mg of secbetstatin (or its pharmaceutical salt and / or solvate).
11. The method of claim 10, wherein the second dose is administered about 2 hours to about 6 hours after the first dose, preferably about 3 hours after the first dose.
12. A method for on-demand treatment of hereditary angioedema (HAE) episodes, the method comprising: Serbetalstat (or its pharmaceutical salt and / or solvate) is administered orally to patients in need as required, wherein a first dose of about 300 mg of serbetalstat (or its pharmaceutical salt and / or solvate) is administered to the patient, followed by a second dose of about 300 mg of serbetalstat (or its pharmaceutical salt and / or solvate).
13. The method of claim 12, wherein the second dose is administered about 2 hours to about 6 hours after the first dose.
14. The method of claim 13, wherein the second dose is administered approximately 3 hours after the first dose.
15. The method according to any one of claims 12 to 14, wherein a third dose of about 300 mg of secbetstatin (or its pharmaceutical salt and / or solvate) is administered to the patient.
16. The method of claim 15, wherein a fourth dose of about 300 mg of secbetstatin (or its pharmaceutical salt and / or solvate) is administered to the patient.
17. The method according to any one of claims 5 to 16, wherein the HAE episode is characterized as "mild" or above according to the PGI-S scale.
18. The method according to any one of claims 5 to 16, wherein the HAE episode is characterized as "moderate" or above according to the PGI-S scale.
19. The method according to claims 5 to 16, wherein the HAE episode is characterized as "severe" or worse according to the PGI-S scale.
20. The method according to any one of claims 5 to 19, wherein the first dose is administered as needed after the symptoms of a HAE attack are identified.
21. The method according to any one of claims 5 to 20, wherein the first dose is administered as needed within approximately 1 hour after the symptoms of an acute HAE attack are identified.
22. The method of claim 21, wherein the first dose is administered as needed within about 50 minutes, about 40 minutes, about 30 minutes, about 20 minutes, about 10 minutes, or about 5 minutes after recognizing symptoms of an acute HAE attack.
23. The method according to any one of claims 1 to 22, wherein sepotestat is in the form of a free base.
24. The method according to any one of claims 1 to 23, wherein the HAE attack is selected from laryngeal attacks, neck and above attacks, non-laryngeal neck and above attacks, abdominal attacks, and subcutaneous attacks.
25. The method of claim 24, wherein the HAE attack is a non-larynx attack occurring in the neck or above.
Citation Information
Patent Citations
Peptide boronic acid inhibitors of trypsin-like proteases
US5187157A
Kininogenase inhibitors
WO1992004371A1
New peptides derivatives
WO1994029335A1
Chemical compounds, their preparation and use
WO1995007921A1
inhibitors
WO2003076458A2
